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Abstract 
Modular domains of proteins are important in cellular signaling processes. Eukaryotic cells are 
constantly undergoing DNA damage due to exogenous and endogenous sources of damage. The 
DNA damage response (DDR) involves a complex network of signaling events mediated by 
modular domains such as the BRCT (BRCA1 C-terminal) domains. Therefore, proteins 
containing BRCT domains are important for DNA damage detection and signaling. In this 
dissertation, we focus on two BRCT-containing proteins BRCA1 and PAXIP1. BRCA1 is a gene 
that is known to be associated with increased risk of hereditary breast and ovarian cancer. 
Germline variants of BRCA1 are assessed to determine lifetime risk of developing breast and 
ovarian cancer. This is performed by genetic testing of the BRCA1 sequence and the variants can 
be classified as pathogenic, non-pathogenic or variants of unknown significance (VUS). Using 
family history, segregation analysis, co-occurrence and tumor pathology, certain variants have 
been classified as either pathogenic or non-pathogenic. However, a large majority of the variants 
are classified as VUS. Functional assays are critical in providing insight in the case of VUS 
results. We have a developed a visualization resource to aid in functional analysis of BRCA1 
missense variants that occur due to single amino acid changes. This tool is known as BRCA1 
Circos (http://research.nhgri.nih.gov/bic/circos/) and it aggregates, harmonizes and allows 
interpretation of data from all published studies on functional analysis of BRCA1 missense 
variants. Therefore, this is an important tool that will aid in the meta-analysis of functional data 
needed to better assess VUS. 
	  	   ix 
Functional studies of BRCA1 also demonstrate that majority of the variants that have a 
functional impact on the protein lie in the BRCT region of the protein. This indicates that the 
BRCT region is important in cancer development.   
To further analyze the function of BRCT-containing proteins, a study was previously 
undertaken to evaluate the role of BRCT-containing proteins and their interaction partners in the 
DNA damage response and consequently, cancer. BRCT domains of seven BRCT-containing 
proteins were used as baits and their binding partners were demonstrated to be highly enriched in 
the DDR process. We hypothesized that members of this BRCT-centric protein-protein 
interaction network could constitute targets for sensitization to DNA damaging chemotherapy 
agents in lung cancer. Therefore, we probed this established dataset containing the protein-
protein interaction network (PPIN) of seven BRCT-containing proteins to identify seventeen 
kinases. A systematic pharmacological screen was performed to evaluate these kinases as targets 
to enhance platinum-based chemotherapy in lung cancer and this revealed WEE1, a mitotic 
kinase, as a potential target. Of the seventeen kinases, inhibition of mitotic kinase, WEE1, was 
found to have the most effective response in combination with platinum-based compounds in 
lung cancer cell lines. In the PPIN, WEE1 was shown to interact with PAXIP1 (PTIP), a BRCT-
containing protein involved in transcription and in the cellular response to DNA damage. 
PAXIP1 has been shown to bind DDR proteins, such as 53BP1 and γH2AX, and also shown to 
be an important part of immune development. In this dissertation, we observe that WEE1 binds 
to PAXIP1 and PAXIP1 regulates the WEE1-mediated phosphorylation of its main substrate, 
CDK1. We also demonstrate that ectopic expression of PAXIP1 combined with WEE1 inhibitor, 
AZD1775, leads to an increase in the mitotic index at the G2/M checkpoint. Overexpression of 
PAXIP1 combined with AZD1775 treatment in cells with prior DNA damage causes high levels 
	  	   x 
of caspase-3 mediated apoptosis as compared to AZD1775 treatment alone. In summary, we 
identify the role of PAXIP1 in sensitizing lung cancer cells to the WEE1 inhibitor, AZD1775, in 
combination with platinum-based therapy and propose the use of WEE1 and PAXIP1 levels as 
mechanism-based biomarkers. Overall, these studies indicate that BRCT-containing proteins 
through their role in the DDR and the cell cycle are crucial for both cancer prevention and 
therapy. 
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Chapter One.  Introduction to BRCT Domains 
 
 BRCT Domains and Their Role in Cancer 
 
  Role of Modular Domains in Signaling. In eukaryotic cells, many biological processes 
in the cell rely on complex signaling mechanisms regulated by protein modular domains [1]. 
Protein modular domains have many functions such as recognizing posttranslational 
modifications, kinase activity, conformational control or acting as scaffolding proteins for 
protein-protein interactions and can fold and function independent of the full-length context. The 
modular nature of these domains lends flexibility as well as fidelity required for normal 
functioning of cellular pathways. Every class of protein interaction domains rely on distinct 
linear peptide motifs that contain a core determinant with flanking residues that are recognized 
by the domain [2]. A large number of modular domains have been identified such as Src 
homology 2 (SH2) [3] or pTyr-binding (PTB) that can recognize phosphotyrosine (pTyr) sites 
phosphorylated by kinases. Some others such as pleckstrin homology (PH) and Phox homology 
(PX) recognize sites phosphorylated by phosphoinositide kinases that are usually membrane 
bound [4].  
Modular domains are approximately 100 amino acids long and are involved in multiple 
processes to sense and relay signals from internal and external sources. Some of the methods by 
which these signaling events occur require physical protein-protein interactions that may be 
dynamic in nature. Therefore, analyzing a protein by dividing it into its domain components
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helps in understanding both structure and function. Homology based data can be used to identify 
new protein domains and to estimate the functional relevance of existing protein domains [5]. 
Databases such as SMART (http://smart.embl-heidelberg.de) [6] and PFAM 
(http://www.sanger.ac.uk/software/pfam/) [7] host data on protein families and domains based on 
sequence alignment information. Individual domains are versatile and can bind different ligands 
at different stages of signaling.	   
 One of the important cellular processes employing modular protein interaction domains 
is DNA damage response (DDR) and repair. Protein kinases, phosphatases and modular domains 
that bind short linear phosphorylated peptides are central to the DDR network. Forkhead-
associated (FHA) domains, 14-3-3 proteins and BRCA1 C-terminal (BRCT) domains cooperate 
to regulate various functions of the DDR process such as foci formation, which is the 
aggregation of DNA damage repair proteins at the sites of damage and in initiating repair [8].  
These phospho-serine/threonine (pS/pT)-binding domains have also been found to be important 
regulators of cell cycle progression [9].  In this dissertation, we focus on the function of specific 
BRCT-containing proteins and their role in the DDR and cell cycle regulation.   
 
Structure and Function of BRCT Domains. The BRCA1 C-Terminus (BRCT) domains 
were first identified in the C-terminus of BRCA1, a gene known to be associated with increased 
risk of hereditary breast and ovarian cancer. The BRCT domain was found to be evolutionarily 
conserved and found in other proteins such as 53BP1 and RAD9 involved in DNA repair, cell 
cycle progression and recombination [10]. In due course, using sequence similarity studies ~40 
nonorthologous proteins belonging to different families were found to contain the BRCT 
domain. In addition to the three discovered initially, the BRCT domain superfamily included 
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proteins such as the fission yeast replication checkpoint protein, Rad4, DNA repair proteins, such 
as DNA-ligases III/IV and XRCC1, and the oncoprotein, ECT2 among others. Most of these 
proteins are large, multidomain proteins that were found to be directly or indirectly related to 
DNA damage response and cell cycle checkpoint control [11,12].  
 The crystal structure of the BRCT domain was initially revealed using X-ray 
crystallography in the human DNA repair protein, XRCC1. The structure comprises of a four-
stranded parallel beta-sheet surrounded by a single alpha-helix (α1) on one side and two alpha-
helices (α2 and α3) on the opposite side (Figure 1) [13]. BRCT domains have a diverse 
architecture in different proteins. They can occur as a single domain, tandem domain or in a few 
cases as a hetero-domain with other protein domains. BRCT domains are known to be phospho-
peptide binding modules which account for their involvement in DNA damage signaling 
processes [14]. Biochemical and structural studies have shown that N-terminal BRCT of the 
tandem BRCT contains a phospho-serine/threonine (pS/pT) binding pocket that is one of the two 
conserved pockets required for phosphopeptide recognition [15,16]. The secondary conserved 
pocket that provides specificity to the phosphopeptide binding is present on the BRCT-BRCT 
interface. This interface consists of the α2 helix of the N-terminal repeat juxtaposed with the α1 
and α3 of the C-terminal BRCT along with a linker connecting the two surfaces (Figure 1). The 
conservation of this interface has been shown to be important, as many missense mutations in 
this interface are known to be involved in carcinogenesis [15]. 
In a study by Manke et al., it was shown that BRCT repeats preferentially bound to 
peptides that were phosphorylated at the serine/threonine sites, especially by DNA damage 
kinases ATM (Ataxia telangiectasia mutated) and ATR (Ataxia telangiectasia and Rad3 related) 
[16]. The binding specificity of the tandem BRCT domains to a linear motif relies on two 
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pockets in the tandem BRCT – one recognizing the phosphorylated peptide and other that 
recognizes the +3 residue of the linear motif [17-19]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Structure of BRCA1 tandem BRCT domain   
Representation of the structure of the BRCA1 tandem BRCT domain (amino acid 1649-1859) 
from the protein data bank (PDB entry 1T29). Each BRCT contains three α helices and a parallel 
four-stranded β sheet connected by a linker region. A phosphopeptide binding pocket is in the N-
terminal BRCT, which is required for recognition of phosphoserine/threonine peptides.  In this 
case the phosphopeptide is a part of BACH1 protein and specificity of binding is indicated by the 
+3 position of a pS/TXXX motif with X being any amino acid.   
 
 
This +3 residue is situated in the hydrophobic interface between two BRCT domains. The 
phospho-binding function of BRCT domains also occurs in single BRCT domains, however, this 
is not as well characterized as the tandem BRCT domains [20,21].  
Besides phospho-peptide recognition, both single and tandem BRCT domains have also 
been known to be involved in phosphorylation independent interactions, poly (ADP-ribose) and 
DNA binding [14].  
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Proteins Containing BRCT Domains. 23 human genes have been found to encode 
BRCT-containing proteins [22]. Figure 2 shows all the known human proteins containing BRCT 
domains. These proteins contain a combination of single BRCT, tandem BRCT (tBRCT) and one 
protein – TOPBP1, contains a triplet BRCT domain. The functions of single BRCT domains are 
not very well defined and, however, the proteins containing tBRCTs have shown to be involved 
in various phospho-dependent and independent signaling processes. Tandem BRCT domains can 
be found in 12 of the 23 proteins - BRCA1, BARD1, TP53BP1, LIG4, TOPBP1, PAXIP1 
(PTIP), ECT2, NBN, MCPH1, XRCC1, MDC1, and ANKRD32 [23]. The tandem BRCT 
structure is folded in a head-to-tail manner and is connected by a linker region, which contributes 
to structural diversity in majority of these BRCT domains [24,25]. BRCT domains recognize the 
linear motif pSXXF in phosphopeptides [15,16,19]. For e.g., BRCA1 uses this phospho-
recognition system to interact with other DDR proteins such as CtIP, BACH1 and Abraxas 
[23,26-29]. However, not all interactions are phosphorylation dependent, such as the interaction 
between TP53BP1 to the important tumor suppressor protein p53 that occurs away from the 
hydrophobic core [30-32].  
 Early studies did not detect the BRCT domain in lower organisms such as Archaea, even 
though bacterial DNA ligases had shown evidence of these domains at their carboxy terminus 
[33]. Recent studies however, have found evidence of BRCT domains in Archaea as it was 
observed that DNA ligases were present in organisms belonging to this kingdom and were 
essential for survival. It was speculated that this occurs due to lateral gene transfer from 
eubacteria [34]. Therefore, even though BRCT-domains have origins from single-cell organisms, 
there are a larger number of BRCT-containing proteins in multicellular organisms with a 
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conserved structure and crucial roles in the DDR process. There are certain exceptions such as 
the ECT2 protein, which is involved in cleavage furrow formation [35] but in a broad sense all 
BRCT-containing proteins are involved in maintenance of genomic stability [36]. 
 The functions of some of the well-studied BRCT-containing proteins are briefly described here:  
 
 
 
 
 
 
 
 
 
 
Figure 2. The BRCT superfamily containing 23 proteins. The red boxes indicate the BRCT 
domains in each of these proteins. This figure is representative only of the BRCT domains in 
each protein. The proteins may contain other non-BRCT domains in certain cases (not shown 
here). Adapted from [22].  
 
BRCA1. BRCA1 is the most well known BRCT-containing protein and it is 
known to contribute to increased susceptibility of breast and ovarian cancer [37]. BRCA1 is a 
pleiotropic gene with many functions. The BRCA1 structure consists of an N-terminal RING 
(Really Interesting New Gene) finger motif, a coiled-coil domain and a C-terminal tandem 
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BRCT region [37]. BRCA1 is mainly involved in DNA damage response signaling. 
Phosphorylation of BRCA1 by DNA damage kinases such as ATM and ATR lead to the initial 
cascade of DNA damaging sensing and consequent repair [38,39]. The majority of BRCA1 
molecules are known to occur in complex with another BRCT-containing protein, BARD1 
(BRCA1-associated RING domain 1) and the two proteins associate at their RING-finger 
domains [40,41]. This BRCA1-BARD1 heterodimeric complex has intrinsic E3 ubiquitin ligase 
activity and cancer causing mutations in the BRCA1 RING domain can lead to the loss of 
ubiquitin ligase activity, causing increased predisposition to breast and ovarian cancer [42-45]. 
The other important functions of BRCA1 include transcriptional regulation [46,47], epigenetic 
regulation and chromatin remodeling as a part of SWI/SWF complex [48-50]. 
 
 MDC1. Mediator of DNA damage checkpoint protein 1 (MDC1) is a BRCT and 
forkhead-associated (FHA) domain containing protein that interacts with γH2AX, a histone H2A 
protein that gets phosphorylated at its serine 139 site in response to DNA damage which leads to 
the recruitment of DNA damage repair proteins to the sites of DNA damage [51]. Mediator 
proteins such as MDC1 aid in the transduction of DNA damage signals from the sites of damage 
to other protein complexes involved in cell cycle regulation and DNA repair. MDC1 is 
phosphorylated both in response to DNA damage/replication stress and during mitosis [51,52]. 
MDC1 binds to the MRN (Mre11-Rad50-Nbs1) complex and in response to ionizing radiation, 
MDC1 forms nuclear foci in an ATM-dependent manner. MDC1 plays an important role in 
activation of the intra-S-phase DNA damage checkpoint and loss of MDC1 leads to 
hypersensitivity to IR and to a radio-resistant DNA phenotype [53]. Many crucial DNA damage 
proteins such as γH2AX, ATM, RNF8, 53BP1 and CHK2 bind MDC1 at its BRCT and FHA 
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domains, indicating an important function for MDC1 in DNA damage response and repair [54-
59]. It also regulates the DDR dependent cell cycle checkpoints and apoptosis by regulation of 
CHK2 and by binding p53 and the anaphase-promoting complex (APC/C) [60,61]. Overall, 
besides the role of MDC1 in DDR, it has also been implicated in other cellular processes such as 
in meiosis and in transition from metaphase to anaphase in mitosis [59].  
 
TP53BP1. p53-binding protein (53BP1 or TP53BP1) is a BRCT-containing 
protein with one C-terminal tandem BRCT (tBRCT) domain that mediates its binding to p53 and 
tandem Tudor domains that are related to its epigenetic functions [62]. 53BP1 acts as a scaffold 
protein to recruit DDR proteins such as RIF1 and PAXIP1 to the DSB sites [63-65]. Through its 
interaction with the MRN complex, MDC1, p53, CHK2 and BRCA1, 53BP1 amplifies ATM 
activity and in turn, regulates the G2/M checkpoint and maintains genomic stability [66-68]. 
53BP1 is also an important factor in determining the type of DNA double-
stranded break repair, non-homologous end joining (NHEJ) or homologous recombination (HR). 
See chapter three for detailed description on both these DNA repair pathways. 53BP1 aids the 
cells in NHEJ-based DSB repair during the G1 phase of the cell cycle [65]. 53BP1 is also 
involved in the regulation of V(D)J recombination and class switch recombination  during the 
development of the immune cells [69,70]. 53BP1 binds to methylated histones (H3K79me) via 
its Tudor domain, which is required for foci formation and DDR functions of 53BP1 [71,72]. 
PAXIP1 is a known binding partner of 53BP1 and is correlated with both its DNA repair and 
immune development functions [73,74].  
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 PARP1. Poly (ADP-ribose) polymerase1 (PARP1) is a nuclear protein that 
contains a single BRCT domain, three zinc finger domains at its N-terminus and a C-terminal 
catalytic domain that transfers ADP-ribose from nicotinamide adenine dinucleotide (NAD+) to 
acceptor proteins (PARylation) [75]. PARP1 is required for the detection of single-stranded 
(SSB) and double-stranded breaks (DSB). In the case of a SSB, the catalytic activity of PARP1 
aids in the PARylation of PARP1 itself. This in turn relaxes the chromatin and other DDR 
proteins such as X-ray repair cross-complementing 1 (XRCC1), DNA Ligase III, polynucleotide 
kinase 3’ phosphatase (PNKP) are recruited to the break site [76,77].  PARP1 also plays a role in 
HR and in NHEJ. PARP1 BRCT is important for the PARylation process and in binding XRCC1 
[78]. PARP1 has been extensively studied as a therapeutic target in cancer therapy [75]. Majority 
of the inhibitors such as olaparib and velaparib target the active enzyme site that binds NAD+. 
The PARP-inhibitor therapies rely on two modes 1) targeting cells that have genetic 
predisposition to PARP inhibition 2) combining PARP inhibitors with DNA damaging agents to 
increase their efficacy [75]. Cells that are BRCA-deficient rely on PARP1 for DNA repair and 
therefore, inhibitors such as olaparib have been used to target tumors that are BRCA-deficient 
[79-81]. Over 50 clinical studies evaluating PARP inhibitors as single agents or combining 
PARP inhibitors with DNA damaging agents are currently ongoing (https://clinicaltrials.gov).  
  
 MCPH1. Microcephalin (MCPH1) is a gene associated with a form of 
microcephaly presenting with a reduced cerebral cortex and mental retardation [82]. MCPH1 
consists of a single N-terminal BRCT domain and one C-terminal tandem BRCT domain [83]. 
MCPH1 is chromatin bound and is required for DNA damage sensing and for regulation of the 
cell cycle [84]. MCPH1 co-localizes with H2AX and binds 53BP1, MDC1 and RPA [85,86]. 
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MCPH1 also regulates the SWI/SWF chromatin remodeling complex increasing the access of 
DDR proteins to chromatin [87]. Depletion of MCPH1 leads to genomic instability and 
centrosomal and chromosomal abnormalities [88].  MCPH1 is located on chromosome 8p23.1, a 
locus commonly involved in breast and ovarian cancer [89,90].  Array comparative genomic 
hybridization studies indicate that MCPH1 copy numbers were decreased in 40% of epithelial 
ovarian cancers [89]. Decreased MCPH1 expression is also observed in other cancers such as 
prostate and breast cancer and MCPH1 status correlated with the occurrence of metastasis in 
these cancers [89,90].  
 
The other BRCT-containing proteins are known to be mainly involved in DNA damage response 
especially double strand break repair, cell cycle, RNA processing and in the case of ECT2, 
cytokinesis [22,91]. 
 
BRCT Domains in Cancer. Genomic instability is a hallmark of cancer regulated by the 
DNA damage response and repair machinery [92]. As the proteins in the BRCT superfamily 
have known functions in DNA damage signaling and repair, germline mutations and alterations 
in the genes that code for BRCT proteins may increase the predisposition to cancer. BRCT 
proteins are scaffold proteins involved in the DDR and some of them such a BRCA1, MCPH1 
and NBN have been associated with increased cancer susceptibility [90]. Of these, germline 
mutations in the BRCT domain of BRCA1 have been extensively studied and documented 
[46,93-99]. Inheritance of one defective copy of the BRCA1 gene increases cancer 
predisposition, however, somatic loss of both alleles is required for cancer to develop [100,101]. 
Germline mutations in BRCA1 present an average cumulative risk of 65% of developing breast 
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cancers by the age of 70 and 40% cumulative risk for ovarian cancer [102]. The tumor 
suppressive functions of BRCA1 in DNA damage response and cell cycle regulation require its 
C-terminal tandem BRCT domain. Protein truncations and missense variants affecting the BRCT 
domain(s) have shown to increase the susceptibility to breast and ovarian cancer [103,104].  
The RING domain of BRCA1 binds to BARD1 and forms a ubiquitin ligase complex 
regulating the catalytic activity of the proteins. The RING domain is another area of the protein 
that is frequently mutated [41,44,105]. A large number of families have now been screened for 
BRCA1 mutations and these mutations are catalogued in the Breast Information Core Database  
(BIC, http://research.nhgri.nih.gov/bic/). Missense mutations of BRCA1 located in the BRCT 
and linker region of protein and lead to incorrect protein folding and unraveling of the BRCT 
structure are more likely to be pathogenic [25,93].  Truncating mutations of BRCA1 are known 
to be deleterious and mice with the truncated Brca1 (missing C-terminal end of the protein) 
exhibit many cancers, including mammary tumors [106]. Met1775Arg (M1775R) is a well-
studied mutation in the BRCT-region that has been shown to be associated with cancer 
susceptibility. This mutation disrupts the BRCT fold and the phosphopeptide binding capacity of 
the protein [107]. However, there are variants whose effect on the protein function cannot be 
assessed using the data available on them and are defined as variants of unknown significance 
(VUS), these will be discussed in the next section.  
 
Mutation Testing in BRCA1 and the Dilemma of Variants of Unknown Significance 
(VUS). Mutations in BRCA1 are identified in probands by sequencing of coding regions of the 
gene [108]. The results from the genetic tests govern the decision for future cancer screening, 
prophylactic mastectomies and oophorectomies and treatment modalities in patients and carriers 
that are screened [109].  These tests were originally performed only by Myriad Laboratories, 
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Inc., but are now performed by multiple laboratories in the U.S. and the results can be broadly 
categorized as 1) “Negative” i.e. no sequence alteration or polymorphism 2) “Positive” or 
pathogenic variant and 3) Variant of Unknown significance (VUS). A negative result indicates 
there is no increased cancer risk compared to the general population that is linked to the mutation 
that was tested [37,110]. It may also indicate that there may be mutations in other susceptibility 
genes such as CHEK2 and ATM [111]. Individuals with a positive result are considered at a 
higher risk of hereditary breast and ovarian cancers as compared to the general population and 
are recommended additional screening. It is the result of VUS that lends no useful information 
when it comes to risk assessment of cancer in individuals undergoing mutation testing [110]. 
Approximately, 10% of Caucasians and 35-50% of Hispanics and African Americans receive a 
VUS result [112-114].   
Majority of the BRCA1 VUS are single amino acid changes or small insertions/deletions 
or intronic mutations that require functional testing, as there is little to no genetic information for 
these variants [50]. Multifactorial models have greatly aided in the classification of VUS using 
family history, sequence conservation and loss of heterozygosity (LOH) data [115-117].  
However, genetic and epidemiological information is not available for all the VUS. Therefore, 
functional assays have been developed to test these variants by assessing their effect on the 
various biochemical functions of the BRCA1 protein. These assays help in classification of 
variants that cannot be classified using pedigree analysis, sequence variation or through loss of 
protein expression [50]. There are many different functional assays that assess the effect of VUS 
on the multiple functions of BRCA1. These assays have been extensively reviewed by Millot et 
al. [110].  
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The C-terminal region of BRCA1 is known to have transcriptional activity and can 
transactivate a DNA binding domain (DBD) fused to a reporter gene. Transcriptional assays have 
been developed based on this characteristic of BRCA1 [46,93,118]. These transcription 
activation assays are performed using the C-terminal end (amino acids 1396-1863) [98]. Variants 
that decrease the transcription activity as compared to wild type are considered to have a 
functional impact on the protein [119]. The transcription activity of wild-type BRCA1 is set at a 
100% and is compared to the activity of protein coded by BRCA1 variants. A known deleterious 
mutation such as M1775R is used as a positive control to compare the BRCA1 variants against. 
To assess pathogenicity and to eliminate batch effects from multiple transcription assays, a 
computational model was developed to classify VUS data by normalizing transcriptional data 
from multiple studies and assigning the variants a probability of being pathogenic. This 
classification model is called VarCall and it normalizes functional data based on a Bayesian 
hierarchical model [120]. Figure 3 depicts the VarCall data from a study that was performed in 
our lab. 219 unique variants have been documented in the C-terminal region of BRCA1, 90 
previously unclassified variants were evaluated in this study and the remaining variants are from 
previously published studies (Unpublished Woods et al. 2015). In the figure, the Y-axis 
represents the log of the posterior odds of the variant being damaging. The green line represents 
the wild-type activity and the red line indicates the proteins that have been previously classified 
as deleterious. The expected posterior probability is represented by the curve on the top [120]. 
This probability-based prediction model is important to normalize experimental data and to 
counter batch effects. This leads to a more robust model so that functional data can be 
objectively analyzed to assign the likelihood of a variant being pathogenic. It is important to note 
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that the majority of deleterious variants lie in the BRCT domains of BRCA1 indicating 
disruptions in this region are highly associated with an increase in cancer susceptibility.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Bayesian model for classification of BRCA1 missense variants.  
Missense variants were tested using transcription activation assays in BRCA1 (aa 1396 - 1863). 
These are then classified using VarCall, a prior probability based model that classifies these 
variants based on functional data (Unpublished data Woods, N.T., Baskin, R., Jhuraney, A. et al. 
2015) 
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Chapter Two. BRCA1 Circos 
 
(Note to reader: Parts of this section have been published in Jhuraney et al. J Med Genet 
doi:10.1136/jmedgenet-2014-102766 [121]. This article is Open Access and when cited, can be 
reproduced for non-commercial use)  
 
Introduction 
Breast cancer is the most common form of cancer in women and 5-10% of breast cancers 
are inherited [122]. Germline mutations in BRCA1 account for 40-45% of hereditary breast 
cancer cases and 80% of ovarian cancer cases in families with multiple cases of breast and 
ovarian cancer [102]. There are over 1,500 unique documented mutations (variants) of BRCA1 
in the Breast Cancer Information Core (BIC) and in various studies. The variants can be 
classified as pathogenic, non-pathogenic or variants of unknown significance (VUS) [110]. The 
missense variants are a large subset of VUS. Due to dearth of data on these missense variants, 
and because majority of the VUS are present in intronic regions, sequence information and other 
genetic information may not be sufficient to infer pathogenicity of VUS [50]. A multifactorial 
statistical model has been developed utilizing segregation analysis, co-occurrence, pathology and 
family history [115,117]. For a VUS result to be classified into a clinically actionable result, this 
multifactorial model has been adapted by the International Agency for Research on Cancer 
(IARC) Unclassified Genetic Variants Working Group. This group developed a five-scale 
classification that has led to classifying previously unclassified variants [116]. 
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The IARC model classified variants from Class 1 to Class 5 with Class 1 having the least 
likelihood of variants being pathogenic (0.1%) and Class 5 having the most likelihood for being 
pathogenic (above 99%). Class 3 variants are classified as “variants of unknown significance”; 
however, as more patients are tested and functional studies performed, fewer variants will fall 
into this category [117,123,124].  
However, due to lack of epidemiological or genetic data on certain missense variants, 
functional assays are required to classify these variants based on their functional impact on the 
protein. Many different functional studie we used PERL-based Circos modules to develop a web-
based visualization tool to develop a comprehensive database documenting functional data on 
missense variants. This tool is known as “BRCA1 Circos” and is available here - 
http://research.nhgri.nih.gov/bic/circos/. BRCA1 Circos documents functional data on ~700 
missense variants in an interactive web-based resource. All the functional assays currently used 
to analyze missense variants are represented in this Circos plot. 
 
Functional Assays. Functional assays are used in a laboratory setting to test VUS by 
analyzing the effect of amino acid changes on the function of BRCA1. Some of the functional 
assays that have been used in literature to test VUS are:  
1) Transcription activation assays have been utilized to assess the function of missense 
variants in multiple studies [46,50,93,95,98,99,119,125-128]. BRCA1 C-terminus consists 
of a coiled-coil motif, a disordered region and one tandem BRCT domain [129]. BRCA1 C-
terminus activates transcription when fused to a heterologous DNA binding domain [46,97]. 
Pathogenic variants in the C-terminal region lead to a decrease in transcriptional activity 
compared to wild type, whereas benign polymorphisms show activity that is similar to wild-
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type BRCA1 [50,104,110]. This assay provides a functional assessment of the integrity of 
BRCA1 C-terminal domain upon the introduction of mutants in that region. Transcription 
assay data has also been used to estimate the likelihood of pathogenicity of variants using 
the probability model VarCall [120].  
2) Small colony phenotype assay [130-132]. This assay is based on the property of BRCA1 
that expression of the protein in yeast leads to small colony size. Wild type BRCA1 and 
benign variants lead to suppression in growth but truncations or missense variants lead to a 
reduction in colony size and number and are potentially pathogenic.  
3) E3-ubiquitin ligase activity assay [43,44]. BRCA1 exhibits ubiquitin ligase activity and 
mutations in the BRCA1 RING domain abrogate its ligase activity. BRCA1 variants may 
alter the ability to bind to BARD1 and the E2 ubiquitin conjugating enzyme and correlates 
with disease susceptibility. 
4)  Phosphopeptide binding assay [119]. In this assay, the BRCT domain of BRCA1 is 
transcribed and translated in vitro and its ability to bind phosphorylated BACH1 protein is 
evaluated.  
5) Protease sensitivity assay [119] Protease sensitivity assay is based on the observation that 
BRCA1 BRCT domains containing a pathogenic mutation were more susceptible to 
protease digestion as compared to wild-type domains.  
6) Embryonic stem cell viability [133] Brca1 is essential for embryonic development and 
embryonic stem (ES) cell viability. Brca1 is inactivated in ES cells and human BRCA1 
containing a variant is ectopically expressed to assess ES viability. ES containing a variant 
that is unable to rescue the phenotype is considered to have a functional impact. 
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7)  Restoration of radiation resistance [134]. Cells that co-express BRCA1 and green 
fluorescent protein (GFP) are mixed with GFP-negative and treated with IR. After 3-24 
days, cells are collected and assayed for a growth advantage as compared to the parental 
cells. GFP-positive cells indicate restoration of radiation resistance akin to the wild-type 
alleles and a pathogenic variant would have a decrease in GFP-positive cells as compared to 
wild type.  
8) Yeast recombination [131] Yeast recombination assay tests the effect of variants by 
measuring recombination events between HIS3 and ADE2 loci. This assay is mainly for the 
BRCA1 BRCT domain.  
9) There are other functional assays to test VUS such as cisplatin response [135], PARP 
inhibitor sensitivity [135], G2/M checkpoint proficiency [43] and homology-directed repair 
[135-137] that test different functions of BRCA1 to assess variants. Majority of these are 
covered in a review by Millot et al. [110] and in the track descriptions 
(http://research.nhgri.nih.gov/bic/circos/trackdescriptions/index.shtml) of Jhuraney et al. 
[121]. All these functional assays and their data have been incorporated in a tool that we 
developed known as BRCA1 Circos.  
 
 
Methods and Results 
 
 Data Sources for BRCA1 Circos. BRCA1 Circos in its current form contains 698 
missense variants reported in literature, the breast cancer information core (BIC) or the NHLBI 
Exome Sequencing Project (ESP6500SI-V2 release) (http://evs.gs.washington.edu/EVS/).  The 
	  	   19 
frequencies of the variants from the BIC database were recorded in the Circos plot. Data was 
also represented from databases such as Align-GVGD 
(http://brca.iarc.fr/PRIORS/BRCA1/index.php)	  and the BRCA1 variant literature database 
(http://chromium.liacs.nl/LOVD2/cancer/home.php). Functional data from published literature 
was recorded in a database of all missense variants and their corresponding functional 
information. The entire BRCA1 database is available at 
http://research.nhgri.nih.gov/bic/circos/allvariants.  
 
Controlled Vocabulary.  Regardless of whether the results from literature were defined 
categorically or quantitatively, a controlled vocabulary was followed [110]. To harmonize the 
scores across all the papers, variants were defined as having a “functional impact”, “no 
functional impact” or intermediate phenotypes with “mild functional impact” and “intermediate 
functional impact”. Functional impact was annotated as follows: N – No functional impact, F – 
Functional impact, I – Intermediate functional impact, M – Mild functional impact and U – 
Undetermined functional impact on the BRCA1 protein (Figure 4). For example, if an article 
representing its functional data quantitatively, we followed the authors’ cut-off to determine 
which variant had a functional impact. Especially for articles that had continuous data, we did 
not have access to raw data and therefore, followed the authors’ decision on functional impact.  
Regarding the assessment of functional impact, it is important to note that functional 
assays or computational data from protein or structural information can be used to assess the 
functional impact but not the pathogenicity, which is a clinical assessment.  
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Figure 4. Harmonizing scores to assess functional impact.  
Controlled vocabulary used to categorize effect of a variant on BRCA1 function. The color code 
specified here has been followed in the BRCA1 Circos plot 
 
On the other hand, a variant that has no detectable functional impact in a specific assay 
may have an effect on BRCA1 function in ways that have not been tested. Therefore, functional 
impact data should be analyzed with caution in a clinical setting.  
 
The Circos Plot. Circos (http://circos.ca) is an open source software that has been used 
to represent genomic data in multiple studies [138]. We used Circos modules to develop BRCA1 
Circos. Each concentric circle in a Circos plot is called a ‘track’. There are 53 tracks in BRCA1 
Circos (Figure 5). Track 1 depicts all the exons of BRCA1. Track 2 represents the frequency of 
the variant in the BIC database and track 3 depicts the IARC class. Track 4-5 depict data from a 
computational model called VarCall that predicts the likelihood of a variant being pathogenic 
based on transcriptional assay data. Table 1 shows all the tracks of BRCA1 Circos and detailed 
descriptions and the key to interpreting them can be found at 
http://research.nhgri.nih.gov/bic/circos/trackdescriptions/index.html. Missense variants are 
shown in track 7-9 (reference amino acid: track 7; codon: track 8, variant amino acid: track 9). 
The remaining tracks show the functional impact on the variant as assessed by different 
functional assays (tracks 11-53).  The function tracks are color-coded as ‘Red’ (functional 
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impact), ‘Blue’ (no functional impact), ‘Yellow’ (mild/intermediate functional impact) or 
‘White’ (no data available). 
 
 
Figure 5. BRCA1 Circos.  
Left Panel BRCA1 Circos without exon 11 to facilitate visualization other the remaining exons 
mainly the C-terminal BRCT domain data. All documented BRCA1 missense variants are 
represented in this plot, which contains 53 concentric tracks depicting functional data.  
Right Panel Magnified view of the exon 21-23 region from the inset in the left panel.  
The website can be used for interactive mouseovers and search functionalities - 
http://research.nhgri.nih.gov/bic/circos/.  
 
 
 
 
Figure 6. Tracks for individual variants.  
A sample slice of the BRCA1 Circos which represents two missense variants – M1775K and 
M1775R. The tracks are color coded to provide functional impact data for all functional assay 
and prediction data.  
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Table 1. Track description for BRCA1 Circos.  
The track names and references for all 53 tracks of the current version of BRCA1 Circos 
 
Track number Description 
Track 1 Exon number 
Track 2 BIC entries (BIC; August 2012) - http://research.nhgri.nih.gov/bic/ 
Track 3 IARC Class (Lindor et al 2012) [117] 
Track 4 
Computational classification of transcriptional assay data (Iversen et al. 
2011)[120] 
Track 5 Bayes' factor (Iversen et al. 2011)[120] 
Track 6 Exome viewer - http://evs.gs.washington.edu/EVS/ 
Track 7 Reference Amino acid 
Track 8 Codon 
Track 9 Variant Amino acid 
Track 10 Align GV-GD -http://brca.iarc.fr/PRIORS/BRCA1/index.php 
Track 11 BARD Binding (Morris et al. 2006)[44] 
Track 12 E2 Binding (Morris et al. 2006)[44] 
Track 13 Ubiquitin ligase activity (Morris et al. 2006)[44] 
Track 14 Ubiquitin ligase activity (Ruffner et al. 2001)[43] 
Track 15 Bimolecular fluorescence complementation (Sarkar & Magliery 2008)[139] 
Track 16 Protease sensitivity (Lee et al. 2010)[119] 
Track 17 Phosphopeptide binding activity (Lee et al. 2010)[119] 
Track 18 Phosphopeptide binding specificity (Lee et al. 2010)[119] 
Track 19 Transcription assay (Lee et al. 2010)[119] 
Track 20 Transcription assay (Carvalho et al. 2009)[95] 
Track 21 Transcription assay (Tischkowitz et al. 2008)[99]  
Track 22 Transcription assay (Carvalho et al. 2007)[96] 
Track 23 Transcription assay (Kaufman et al. 2006)[125] 
Track 24 Transcription assay (Phelan et al. 2005)[98] 
Track 25 Transcription assay (Mirkovic et al. 2004)[126] 
Track 26 Transcription assay (Worley et al. 2002)[128] 
Track 27 Transcription assay (Vallon-Christersson et al. 2001)[93] 
Track 28 Transcription assay (Monteiro et al. 1996)[46] 
Track 29 Transcription assay (Lovelock et al. 2006)[140] 
Track 30 Transcription assay (Ostrow et al. 2004)[141] 
Track 31 Transcription assay (Quiles et al. 2013) [127] 
Track 32 Transcription assay (Kawaku et al. 2013) [142] 
Track 33 Small Colony Phenotype (Coyne et al. 2004)[132] 
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Table 1. (Continued) 
Track 
number Description 
Track 34 Small Colony Phenotype (Humphrey et al. 1997)[143] 
Track 35 Small Colony Phenotype (Caligo et al. 2009) [131] 
Track 36 Small Colony Phenotype (Millot et al. 2011)[130] 
Track 37 Yeast localization phenotype (Millot et al. 2011)[130] 
Track 38 ES Viability (Chang et al. 2009)[133] 
Track 39 ES Viability (Bouwman et al. al 2013) [135] 
Track 40 Restoration of radiation resistance (Scully et al. 1999)[134] 
Track 41 Increase/restoration in radiation resistance (Ruffner et al. 2001)[43] 
Track 42 Homology-directed repair (Ransburg et al. 2010)[137] 
Track 43 Homology-directed repair (Towler et al. 2013) [136] 
Track 44 Homology-directed repair (Bouwman et al. 2013)[135] 
Track 45 Single strand annealing (Towler et al. 2013) [136] 
Track 46 Centrosome number (Kais et al. 2012)[144]  
Track 47 Yeast Intrachromosomal recombination (Caligo et al. 2009)[131] 
Track 48 Yeast Interchromosomal recombination (Caligo et al. 2009)[131] 
Track 49 G2/M Checkpoint proficiency (Ruffner et al. 2001)[43] 
Track 50 
Subcellular localization/formation of foci after IR (Au & Henderson 
2005)[145] 
Track 51 
Subcellular localization/ cytoplasmic mislocalization (Rodriguez et al. 
2004)[146] 
Track 52 Cisplatin response (Bouwman et al. 2013) [135] 
Track 53  PARP inhibitor sensitivity (Bouwman et al. 2013) [135] 
 
The website - http://research.nhgri.nih.gov/bic/circos/ has various functionalities. They are as 
follows: 1) Mouse-over to zoom into any region of the Circos plot; 2) All tracks and data points 
are hyperlinked to the database containing the information; 3) Double-clicking any part of the 
figure zooms into that region so the user can pan the image; 4) All tracks are hyperlinked to the 
original articles where the data was taken from; 5) Detailed track descriptions of every functional 
assay represented in the Circos plot.  
BRCA1 Circos helps in the meta-analysis of missense variants. However, functional 
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overlap between the various assays should be considered before deciding the overall functional 
impact of a missense variant. Therefore, BRCA1 Circos is an important tool for the analysis and 
interpretation of BRCA1 VUS. 
 
Discussion 
 Inactivating mutations in BRCA1 are correlated with an increased susceptibility of 
hereditary breast and ovarian cancer [37,147]. Genetic testing is important to identify individuals 
that are at high risk of developing breast and ovarian cancer. Current genetic testing methods are 
sequence-based and identify alterations in the DNA used to infer the effect of the alteration on 
the protein product. Variants that cause truncation of the protein lead to suppression of wild-type 
BRCA1 and can be deemed pathogenic for clinical purposes. However, variants whose effect 
cannot be assessed by sequence alterations alone are known as variants of unknown significance 
[117]. These VUS are mainly missense variants that result due to a single amino acid change and 
as a result of variants that affect splicing of the transcript.  
 Family studies, epidemiological data and co-occurrence data may not be available for 
majority of these variants. Many prediction tools and functional assays have been developed to 
classify these VUS to make them more clinically actionable [110]. BRCA1 is a pleiotropic gene; 
and it is not known which function of BRCA1 leads to an increase in cancer susceptibility. 
Nevertheless, it has been shown that functional data is strongly correlated with pathogenicity and 
can be used for VUS classification [119]. A computational model called VarCall was developed 
to allow incorporation of functional data to generate likelihood ratios to classify variants [120]. 
To facilitate analysis of all the documented functional data, we developed a database and a 
visualization tool to display the available functional data for VUS. This tool provides a global 
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view of functional data for all documented missense variants. It also provides clinicians and 
other people involved in BRCA1 research a method to navigate different functional assays and 
get an overview of the data from several sources.  There are databases that are currently available 
to view VUS information such as the Breast Cancer Information Core (BIC) 
(http://research.nhgri.nih.gov/bic/) and the LOVD BRCA1/2 literature 
(http://chromium.liacs.nl/LOVD2/cancer/home.php) database. However, there was a lack of 
comprehensive databases to that utilize a controlled vocabulary masking it easy to interpret and 
visualize functional data before the development of BRCA1 Circos. This new resource is web-
based and updatable and the data in the BRCA1 Circos missense variant database classifies 
variants based on functional impact such as having a ‘functional impact’, ‘no functional impact’ 
or ‘mild/intermediate impact’ on BRCA1 protein function. This aids in combining the 
information from multiple studies representing both quantitative and qualitative data. The 
website has multiple functionalities such as zooming in and linking every data point to its 
original article. This is a truly interactive tool that will be used to document and analyze 
missense variants and also as a platform for documentation of variants of other susceptibility 
genes such as BRCA2, work on which has already begun by members of the ENIGMA 
consortium (http://enigmaconsortium.org/). In conclusion, BRCA1 Circos is an open-source 
resource that will be used to visualize complex data and serves as an important research and to 
some extent a clinical resource for functional analysis of VUS.  
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Chapter Three. Background  
 
DNA Damage Response (DDR) Network 
 
 
DNA Damage and Repair: The Process. Eukaryotic cells undergo DNA damage as a 
result of both physiological processes within the cell and external sources such as chemicals, 
ultraviolet radiation (UV) and ionizing radiation (IR). In order to preserve genome integrity from 
one generation to the next, multiple mechanisms have evolved, collectively labeled the DNA 
damage response (DDR) [148]. The DDR is required to detect DNA lesions and to relay signals 
from the site of damage and allow for repair mechanisms to initiate in coordination with the cell 
cycle [149]. The DDR is a network consisting of many complex pathways that work in tandem 
for effective signaling and repair. Programmed DNA damage mechanisms also occur as a part of 
genomic rearrangement during cellular development in lymphocytes and germ cells [149,150]. 
Therefore, the DDR is a constant process within a cell and errors in DNA damage sensing and 
repair can lead to genomic instability and in turn to many different diseases including cancer 
[151,152].   
 The initial studies on the DDR focused mainly on the kinase cascade activated as a result 
of DNA damage and replication. These kinases belonged to protein complexes that were 
arbitrarily divided into sensors, mediators, effector protein kinases and substrates [153]. The 
main DDR complexes are those that contain the phosphatidylinositol 3-kinase-like protein 
kinases (PIKKs) family of kinases - Ataxia telangiectasia mutated (ATM), Ataxia telangiectasia 
and Rad3 related (ATR) kinase, and DNA-PK complexes [148,153].
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The ATM kinase is activated as a response to DNA double stranded breaks (DSB) and the 
mediator complex – Mre11/Rad50/Nbs11 (MRN) sensing the break and recruits ATM to the site 
of damage [154]. DSB formation occurs as a result of IR, certain chemotherapeutic agents and 
other cellular events such a V(D)J recombination in lymphocytes. If left unrepaired these breaks 
can lead to genomic instability and chromosomal breaks [149,155]. The ATR kinase is activated 
during S phase and regulates replication origin firing by recruitment to replication protein A 
(RPA) coated sites of single-stranded DNA (ssDNA) breaks during DNA replication [156].  
 Multiple protein complexes are involved in sensing the damage and localization of sensor 
proteins to the sites of damage can lead recognition of DNA breaks and activation of the DDR 
[152]. DSB repair can occur via multiple pathways, the two well known of these are homologous 
recombination (HR) and nonhomologous end-joining (NHEJ) (Figure 7) [157,158]. Some other 
mechanisms of DSB repair are alternative-NHEJ (alt-NHEJ) and single-strand annealing (SSA) 
[148]. The selection of the mechanism of repair depends upon the extent of DNA repair and 
DNA end processing required. Classical NHEJ can occur throughout the cell cycle and is 
dependent upon DNA-PKcs, Ku70, Ku80 and DNA ligase IV to repair the DNA ends but 
alternate-NHEJ pathways sometime exist if the components of the classical NHEJ pathway are 
mutated or missing [159,160]. On the other hand, HR requires a homologous DNA strand, 
usually a sister chromatid, as a template for repair and therefore, occurs in S and G2 phases of 
the cell cycle [161]. After the generation of the ssDNA from the DSB, the initial steps of HR 
utilize Rad51 recombinase to attach to the DNA ends to intiate repair and activation of ATR to 
regulate the cell cycle [162]. After repair, 5′-to-3′ resection occurs in HR leading to an error-free 
process which does not occur in NHEJ [161].  
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Figure 7. DNA repair pathways involved in repairing double-stranded breaks.  
The main components and signaling cascade of different DNA damage and repair pathways. 
Adapted from [148,163].  
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In this dissertation, we will use DNA damaging agents such as ionizing radiation (IR) and 
platinum-based compounds such as cisplatin (cis-diammine-dichloro-platinum). Cisplatin is a 
therapeutic agent that has been used in the management of many tumor types since the past 35 
years [164]. Both these agents cause different types of DNA damage. IR leads to DSBs [165] and 
the platinum in cisplatin crosslinks with the N7-sites of purine bases in DNA which disrupts the 
structure of DNA. This forms cisplatin-DNA adducts that form DNA lesions that are responsible 
for the cytotoxicity imparted by cisplatin [166]. 
 
Sensors, Mediators and Effector Proteins. The DDR relies on multiple protein 
complexes at every step from sensing the damage to eventual repair or if the DNA is not 
repaired, signaling the cells to undergo apoptosis (Figure 8). As soon as DNA damage occurs, 
the three main kinases, which are activated and recruited to the sites of damage, are ATM, ATR 
and DNA-PKcs [167]. The ATM and DNA-PKcs kinases primarily detect DSBs, whereas ATR 
detects ssDNA breaks during replication [38]. The Mre11/Rad50/Nbs1 (MRN) complex, which 
is a substrate of ATM, senses the damage and recruits ATM to the DNA break site [154]. This is 
important for downstream signaling where ATM/ATR phosphorylate the effector kinases CHK1 
and CHK2. Phosphorylated and activated CHK1 and CHK2 kinases regulate downstream targets 
such as p53 and Cdc25 phosphatases, which activate cell cycle arrest/delay for repair to be 
undertaken [153,168]. In the case of stalled replication forks, the RPA complex recruits ATR 
through its binding partner ATRIP and then the Rad9-Rad1-Hus1 (911 complex) is loaded onto 
the DNA. Certain BRCT-containing proteins such as TopBP1 are also known to have a role in 
DNA replication and are phosphorylated by ATM/ATR to regulate checkpoint signaling 
[149,153]. Another BRCT-containing family of proteins PARP1 and PARP2 are recruited to the  
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Figure 8. The DNA damage response pathway. The DNA damage response pathway 
constitutes of sensors such as the Mre11/Rad50/Nbs1 (MRN) complex, transducers such as the 
ATM and ATR kinases and effector kinases such as CHK1 and CHK2. These collectively 
respond, signal and control transcription, cell cycle arrest in case of DNA damage and 
consecutive, repair. In the event, that the DNA damage cannot be repaired, the cells undergo 
apoptosis. Adapted from [152]. 
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 sites of SSB or DSBs and add poly (ADP-ribose) chains on proteins for recruitment of DDR 
proteins to the DNA breaks [169]. Downstream of ATM and ATR kinases are substrates that act 
as mediators both by recruiting substrates and by acting as scaffolds for protein complexes. 
Many of these mediators are BRCT-containing proteins, such as MDC1, BRCA1, 53BP1, and 
MCPH1 and non-BRCT containing proteins, such as claspin and the MRN complex [153]. The 
assembly of these factors at the break sites leads to formation of discernible foci in the nucleus. 
The main target of the DNA damage kinases is a histone H2A variant γH2AX, which is 
phosphorylated at Ser139 and recruited by MDC1 [170]. The tandem BRCT of MDC1 binds 
directly to γH2AX and acts to amplify its phosphorylation [171]. Another mediator and tBRCT-
containing protein, 53BP1 is also recruited to the damage site leading the formation of IR-
induced foci (IRIF) along with H2AX, MDC1 and other factors. These IRIF are considered an 
early hallmark of DNA damage and serve as surrogates of DNA damage to help in the 
visualization of genomic instability [153]. Phosphorylated MDC1 interacts with and recruits an 
E3 ubiquitin ligase RNF8, which catalyzes the ubiquitination of histones, mainly H2AX and 
some other proteins [58,172,173]. Ubiquitination of H2AX recruits 53BP1 and BRCA1 at the 
break sites. BRCA1 is recruited using the protein complex of Rap80 and phosphorylated Abraxas 
[174,175]. 53BP1 recruitment at the IRIF sites is H2AX, RNF8 and MDC1-dependent 
[51,58,176,177] and also requires the methylation of histones H3 and H4 [71,178] and Tip60 
histone acetyltransferase activity [179]. 53BP1 in turn recruits other proteins such as PAXIP1 to 
the DSB sites [64]. Multiple protein complexes are recruited, however, not all of them are 
employed in the signaling and repair at the same time and this redundancy in the system ensures 
that the critical process of DNA repair and replication occurs without a glitch.  
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 ATM and ATR phosphorylate a large number of substrates in response to DNA damage by UV 
or IR, respectively [180]. The effector proteins are a wide variety of proteins involved in DNA 
replication, mismatch repair, DNA polymerase complexes, cell cycle regulation and many other 
processes. Large-scale studies have been undertaken to detect protein complexes that play a role 
in DNA damage response and downstream processes of the DDR [153]. One such study was 
undertaken in our lab to develop a DDR network using BRCT-containing proteins as the central 
focus [22]. This led to the discovery of multiple novel functional complexes in the DDR and will 
be described in detail in later sections of this dissertation. 
 
Cell Cycle Regulation of the DDR. The cell cycle progresses due to the coordination of 
CDKs with cyclin proteins that are transiently expressed at different stages of the cell cycle. 
Phosphorylation and dephosphorylation of various substrates are required for the CDK-cyclin 
complexes to ensure the accuracy of the cell cycle progression machinery. Cell cycle regulation 
also requires checkpoint control, which is required to sense DNA damage and during DNA 
replication and chromosomal segregation during cell division [181]. It has already been 
discussed that certain DNA repair mechanisms such as NHEJ and HR occur in specific phases of 
the cell cycle. HR occurs in the case of a DSB in the S and G2 phases of the cell cycle and NHEJ 
occurs in the G1 phase. The coordination of the DDR along with the cell cycle is controlled by a 
set of kinases known as cyclin-dependent kinases (CDKs) [182].  The ATM, ATR and DNA-PK 
kinases are central to the checkpoint regulation process as they are to the DNA damage sensing 
and signaling process [183]. The different cell-cycle specific mechanisms that occur during the 
DDR are described here: 
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DNA Repair During the G1 Phase. In eukaryotic cells, the G1 phase of the cell cycle is 
for the preparation of S phase to initiate DNA synthesis. When cells are in G1 phase, they need 
to repair any DNA damage that occurs due to endogenous or exogenous sources of damage. The 
damage should ideally be repaired before DNA replicates, as DNA lesions can stall replication in 
later stages of the cell cycle [182]. In case of damage the proteins that are involved in cell cycle 
arrest are ATM, ATR, CHK1, CHK2, p53, MDM2 and p21 [184]. ATM phosphorylates p53 at 
the serine 15 site, which binds the ubiquitin ligase MDM2, and leads to the stabilization of the 
p53-MDM2 complex. p53 is also phosphorylated by CHK1 and CHK2 and it regulates the 
transcriptional activity of downstream factors such as p21 [184]. p21 inhibits the cyclinE/CDK2 
kinase complex leading to G1 arrest in case of DNA damage. In late G1, cells decide to enter the 
S phase and the phosphatase activity of Cdc25A is needed to dephosphorylate the inhibitory 
phosphorylation of the tyrosine 15 (Tyr15) of CDK2 to initiate the G1/S transition [185,186]. 
The p53 and Cdc25A pathways are temporally separated, as p53 is dependent on transcription 
and synthesis [185].  
 
DNA Repair Mechanisms During the S Phase and the Intra-S-Phase Checkpoint. S 
phase is the stage of the cell cycle where DNA synthesis occurs and is therefore, associated with 
inherent problems of replication fork collapses, misincorporated nucleotides and other DNA 
breaks due to replication [182,187]. Base pair mismatches and small insertions/deletions are 
repaired by the mismatch repair (MMR) pathway [188].  The DNA replication S-phase 
checkpoint is regulated by the ATR-ATRIP complex and the 911 complex. The main function of 
this checkpoint is to inhibit replication initiation by stalling the replication forks and to allow 
checkpoint recovery once the damage has been repaired [189-191]. The intra-S-checkpoint is 
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replication-independent and is usually induced by DSB due to exogenous sources such as IR. 
Activation of the intra-S-checkpoint leads to decreased DNA synthesis and defects in this 
checkpoint post IR can result in defective DNA synthesis leading to radioresistant DNA 
synthesis (RDS) phenotype [168,191]. RDS is observed in cells that are depleted of the important 
damage sensing and signaling proteins such as ATM, ATR, CHK1, CHK2, NBS1, 53BP1, 
BRCA1 and BRCA2 [191]. The ATM and MDC1-MRN-dependent phosphorylation of SMC1 is 
required to stall DNA replication post IR-induced damage [192,193]. Another pathway is 
activated by the phosphorylation of H2AX by ATM and consequent recruitment of the MDC1, 
53BP1, BRCA1 and MRN complex [191,194].  
 ATM phosphorylates SMC1 and BRCA1 to initiate the intra-S-checkpoint activation 
[184,195]. Apart from the ATM-NBS1-SMC1 axis, the other branch of the intra-S-checkpoint is 
the ATM-CHK2-Cdc25A-Cdk2 pathway [196]. CDC45, a protein required for the assembly of 
DNA polymerase at the pre-replication origins, fails to load onto chromatin due to signaling 
through this pathway [191,197]. These two pathways functioning in parallel occurs both as a 
result of exposure to IR and UV radiation [196,198]. All the major G1/S checkpoint proteins are 
considered tumor suppressor proteins and hereditary mutations in ATM [199,200], CHK2 [201], 
BRCA1 [202] , p53, Mre11, Nbs1 etc. have been known to be associated with increased risk of 
developing inherited cancers. Therefore, this checkpoint is crucial in the early stages of 
carcinogenesis and is important for diagnostic and therapeutic purposes [185].  
 
DDR at the G2/M Checkpoint. Once the cells have committed to dividing, the final 
checkpoint to detect any DNA damage before the cells enter mitosis is the G2/M checkpoint 
[168,203]. One of the most critical events at the G2 /M is the activation of the Cyclin B/CDK1 
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kinase that is dephosphorylated by CDC25C phosphatase to activate the complex and for the 
cells to transition from G2 to M (Figure 9) [184,204,205]. 
  
 
    
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. G2-M checkpoint activation as a result of DNA damage.  
The ATM kinase responds to double stranded breaks (DSBs), ATR activation occurs due to a 
single-stranded breaks (SSBs). Downstream kinases such as CHK1 and CHK2 are activated and 
CDK1 is inactivated by being phosphorylated by WEE1 family kinases. After DNA repair has 
occurred, CDC25 dephosphorylates CDK1 and WEE1 is degraded for the G2-M transition to 
occur. Adapted from [182]. 
 
In case of external stresses, the ATM-CHK1 and/or the ATR-CHK2 pathway inhibit the 
activation of the cyclin B/CDK1 complex by phosphorylating and inactivating the CDC25C 
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phosphatase [168,189,206]. The upstream kinases that phosphorylate the CDKs such as PLK1 
and WEE1 are also important to regulate the G2/M transition after DNA damage. The G2 phase 
of the cell cycle also relies on the transcriptional regulation by p53 and BRCA1 leading to higher 
expression of proteins such as p21, 14-3-3 sigma and GADD45a [184,207]. Therefore, cells that 
have a p53 mutation [208,209] or a defective G1 checkpoint rely more on the G2/M arrest for 
accurate repair before mitosis [210]. As many tumors are p53 mutant, the effect of cytotoxic and 
DNA damaging agents such as radiation and chemotherapeutic agents can be enhanced by 
abrogating the G2/M checkpoint [211]. CHK1 and WEE1 kinase inhibitors are currently being 
tested to achieve this and a WEE1 inhibitor, AZD1775 (MK-1775) [212] will be the focus of this 
dissertation.  
 However, the issue of analyzing DDR at the G2/M is slightly complex, as it has been 
shown by Xu et al. that there are two molecularly distinct G2/M checkpoints – the early G2/M 
checkpoint and the G2 accumulation checkpoint [203]. The activation of these checkpoints is 
dependent on the time that has elapsed post IR.  Both of these checkpoints are controlled by 
independent signaling mechanisms. The early G2/M checkpoint occurs early after IR (1-2 h) and 
is transient and ATM-dependent but dose-independent. On the other hand, the G2/M 
accumulation checkpoint is ATM-independent and dose-dependent (1 to 10Gy IR) and occurs at 
a later time point (for e.g. After 16 hours post IR). Therefore, the early time point measures the 
cells that were in G2 and failed to progress to mitosis after irradiation. The G2 accumulation 
checkpoint measures the cells that were in S or G1-phase at the time of irradiation and should be 
analyzed by propidium iodide or DAPI staining. Therefore, it is important to analyze the cells at 
the correct time point to obtain the desired results [203].  
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 CDK-dependent phosphorylation has been shown to impair the interaction between BRCA2 and 
RAD51 inhibiting HR [213]. The CDK activity is required for processing of DSB into ssDNA 
and for induction of G2 arrest for HR to be promoted [182]. Overall, the different cell cycle 
checkpoints are required for DNA damage detection and repair before the cell enters mitosis and 
are regulated by multiple pathways functioning in parallel. 
 
Spatiotemporal Regulation of DDR Proteins. The DDR is tightly coordinated when it 
comes to spatiotemporal organization of the DDR complexes at the site of the DNA breaks. One 
of the main methods of detecting DNA breaks is the formation of foci formed by the 
accumulation of DDR proteins at the sites of damage. However, not all proteins translocate to the 
DNA damage sites and some like the Chk1 and Chk2 kinases become phosphorylated at the DSB 
sites and then dissipate through the entire nucleus [161]. In a study by Bekker-Jensen et al., DDR 
proteins were classified into three groups based on their spatial distribution: proteins associated 
with the DSB-flanking chromatin, protein complexes at the ssDNA microcompartments and 
proteins with no retention at DSBs [214]. DSB-associated proteins tend to form foci that increase 
in size as time progresses. DSB-flanking chromatin proteins such as γH2AX spread away from 
the DSB into the adjacent chromatin [194,215]. Other DSB-flanking chromatin proteins are 
ATM, MRN complex and BRCT-containing proteins MDC1, BRCA1 and 53BP1. These 
proteins can assemble at all stages of the cell cycle [214].  
 Proteins such as CtIP, RPA, ATR, BRCA1/2 and RAD51 that bind to the ssDNA 
microcompartments, are active in cells that are in the S/G2 phase of the cell cycle [214,216]. Cell 
cycle regulation of BRCA1 and CtIP is dependent on CDKs [217]. Complexes that do not stay at 
the DSB site are DNA-PKcs, Ku70, Chk1/2 and p53. Certain proteins such as Nbs1 and BRCA1 
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can interact both with the DSB-flanking chromatin and ssDNA strands [214].  The interplay 
between the different protein complexes is controlled by foci formation, which allows for the 
concentration of repair factors at the chromatin and away from other sites in the nucleus such as 
replication forks. Checkpoint and repair proteins co-localize at damage sites to allow for 
coordination between the cell cycle and repair processes. This leads to maintenance of genomic 
stability through a delicately managed series of events. 
 
 
 
 PAXIP1: Structure and Functions 
 
 
The Structure of PAXIP1. The PAX interacting (with transcription-activation domain) 
protein 1 (PAXIP1) gene (also known as PTIP) locus is located on chromosome 7q36 and codes 
for 1069 amino acids [64,218]. PAXIP1 contains three tandem BRCT (tBRCT) domains – the N-
terminal tBRCT pair N1 and two C-terminal tBRCTs, pair C1 and C2 and a polyglutamine-tract 
(Q) region. PAXIP1 was first discovered in a yeast-2-hybrid (Y2H) screen binding to Pax2 
[218], a protein known to be highly expressed in Wilms’ tumor and renal cell carcinomas 
[219,220]. The various domains and motifs in PAXIP1 are shown in Figure 10 and summarized 
in Table 2. It has been shown using gel-filtration assays that two distinct pools of PAXIP1 exist 
in vivo, a higher molecular weight pool (over 2MDa) containing the histone methyltransferase 
(HMTase complexes) and a lower molecular weight pool (less than 200kDa) containing a 
complex of PAXIP1 and its direct binding partner PA1 (PTIP associated 1) [221-223]. PA1 
binds to the tBRCT pair N1 (amino acids 8-183) of PAXIP1 and specifically requires the second 
BRCT of the tBRCT pair N1 for the interaction. Using PAXIP1 knockdown cells, it has been 
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shown that PAXIP1 is required for PA1 foci formation at the sites of ionizing radiation (IR)-
induced DNA damage [222].  
PAXIP1 and PA1 foci formation after DNA damage also requires the signaling cascade 
of γH2AX, MDC1 and RNF8. The presence of PAXIP1 at the sites of DNA damage is dependent 
on RNF8/UBC13 ubiquitination processes [173,222]. The PAXIP1/PA1 complex is also required 
for G2/M checkpoint regulation and cell survival post IR. PAXIP1 and PA1 bind MLL (mixed 
lineage leukemia) proteins [221,224], however, the DNA damage functions of the PAXIP1/PA1 
complex seem to be independent of their association with the MLL complex [222]. Therefore, 
this indicates that the PAXIP1/PA1 association occurs in a separate pool in vivo.  
 
 
Figure 10. PAXIP1 structural organization. Schematic representation of the structure of 
PAXIP1. The protein contains 6 BRCT (BRCA1 C-terminus) domains (three tandem BRCT 
domains) and a central region that is glutamine (Q) rich. Adapted from [223]. 
 
PAXIP1 has two tBRCT domains at its C-terminal end (amino acids 597-1069) [64,218]. 
In an initial study on BRCT-containing proteins, it was shown that a fragment of PAXIP1 
containing the two C-terminal BRCT pairs bound to a phosphopeptide library containing 
phospho-Ser/Thr motifs [16]. The library was biased to resemble phosphorylation motifs specific 
to the DDR kinases ATM and ATR to identify BRCT-containing proteins important for DNA 
damage signaling [225,226]. In general, tandem BRCT domains recognize the consensus 
sequence pSer-X-X-Phe (X being any amino acid) in phosphoproteins and peptides. Specifically, 
the C-terminal tBRCT domain pair C2 preferentially binds to peptides containing the p-S/T-Q-V-
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F motif. In contrast, neither of the single BRCT domains was able to bind the phosphopeptides 
showing that the C-terminal tBRCT domains need to function as a single module to bind 
phosphorylated peptides. The N-terminal tBRCT domain did not bind to the peptide library 
indicating that not all tBRCTs of PAXIP1 have phospho-recognition and binding functions [16]. 
Endogenous PAXIP1 has been demonstrated to bind another tBRCT-containing protein, 
TP53BP1 that is phosphorylated at its Ser25 site. The binding of TP53BP1 to PAXIP1 requires 
not just one C-terminal tBRCT domain but both tBRCTs pair C1 and C2 to be intact. This 
interaction is dependent on ATM and occurs after cells have been exposed to IR [64]. The C-
terminal end of PAXIP1 also contributes to its transcriptional regulatory functions due to its 
association with HMTase complex proteins such a MLL2, MLL3 and MLL4 [221,224,227]. A 
study by Woods et al. developed a protein-protein interaction network (PPIN) of seven tBRCT 
containing proteins including the tBRCT pair C2 of PAXIP1. Using literature curation, tandem 
affinity purification based mass spectrometry (TAP-MS) and Yeast-2-hybrid (Y2H) experiments, 
210 interactors were found to bind the pair C2 of PAXIP1. Majority of these interactors were 
found to be proteins involved in cell cycle progression and DNA damage signaling confirming 
the role of PAXIP1 in these processes [22]. X-ray crystallography based structural analysis 
demonstrated that the tBRCT pair C2 of PAXIP1 binds to the γH2AX tail and requiring the 
phosphorylation of H2AX at its Ser139 site indicating that this interaction may govern the role of 
PAXIP1 in early response to DNA damage [228]. In Xenopus laevis, Ptip/Swift bound the 
Smad2-Smad4 complex (part of the TGFβ signaling cascade [229]) at its C-terminal domain and 
aided in gene transcription [230].  
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Table 2. PAXIP1 domains and motifs and their functions. tBRCT – tandem BRCT domain, Q 
– glutamine, S/T-Q-V-F – Serine/threonine-glutamine-valine-phenylalanine, NLS – Nuclear 
localization signal 
 
The polyglutamine rich (Q) region (amino acids 402-590) of PAXIP1 has not been as 
well studied as the BRCT domains of the protein. However, it has been shown that deletion of 
the Q region had little effect on PAXIP1 foci formation after IR exposure. Ptip-/- mouse 
embryonic fibroblasts (MEFs) have lower cell survival than Ptip wild-type MEFs but 
reconstitution with BRCT1, 5, 6 or the Q region can increase cell survival to a level similar to the 
wild-type cells [222]. Introduction of only the Q region in mammalian cells did not lead to 
nuclear localization of PAXIP1 upon IR exposure but deletion of this region alters the PTIP 
Domains	  and	  motifs	   Amino	  acids	   Functions	   Refs	  
tBRCT	  –	  pair	  N1	   8-­‐183	  
Interaction	  with	  PA1	  for	  DNA	  damage	  signaling	  and	  cell	  cycle	  progression	   [222]	  
Q	  region	   402-­‐590	   Cell	  survival	  and	  foci	  formation	   [222,	  231]	  
tBRCT	  –	  pair	  C1	   597-­‐779	   Phospho-­‐peptide	  recognition	  along	  with	  pair	  C2	   [223]	  
tBRCT-­‐pair	  C2	   866-­‐1059	   Interaction	  with	  MLL2	  and	  with	  phospho-­‐S/T-­‐Q-­‐V-­‐F	  motifs,	  Interaction	  with	  γH2AX	   [16,	  221,	  228]	  
tBRCT	  –	  pair	  C1	  and	  C2	   597-­‐1059	   Recruitment	  to	  double-­‐stranded	  breaks,	  Interaction	  with	  phospho-­‐Ser25	  53BP1,	  Interaction	  with	  Smad2	  	   [64,	  230]	  
	  NLS	   842-­‐852	   Nuclear	  import	   [64]	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localization pattern post IR. This indicates that the Q region is necessary but not sufficient for the 
DNA damage response functions of PAXIP1 but does play a role in cell survival and foci 
formation after DNA damage. Another aspect of the glutamine-rich region of PAXIP1 relates to 
poly-Q expansion related degenerative diseases such as Huntington's disease and spinal and 
bulbar muscular atrophy (SBMA) etc. PAXIP1 interacts with poly-Q expansion proteins through 
its Q region and inhibits DNA damage repair and gene regulation, potentially resulting in these 
disorders	  [231]. 
 The BRCT and Q regions constitute majority of the protein and the only other known 
motif in the PAXIP1 sequence is the nuclear localization signaling motif (amino acids 842-852) 
required for efficient import into the nucleus and for localization to chromatin in the presence of 
DNA lesions [232]. Certain other sites of PAXIP1 have also been studied. Mutating PAXIP1 at 
its Trp676 site (W676A) or Trp929 (W929A) site disrupts the formation of IR-induced nuclear 
foci by the protein. Another mutation in the Q-region, R910Q abolishes binding of PAXIP1 to 
phospho-Ser25 TP53BP1 but does not affect nuclear foci formation by PAXIP1 [233].   
In this dissertation, we will focus mainly on the BRCT domains of PAXIP1 and their role 
in cell cycle progression and DNA damage response. 
 
PAXIP1: Biological Processes and Biochemical Functions 
PAXIP1 plays a role in many different biological processes and biochemical functions. 
Since it is not a very well studied protein, there are still many unanswered questions on the exact 
function of PAXIP1 in majority of the processes it is involved in. Some of the known functions 
of PAXIP1 are explained in detail here. 
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Role of PAXIP1 in the Maintenance of Genomic Stability. Murine studies have shown 
that embryonic stem (ES) cells with a constitutive null Ptip allele have severe developmental 
defects and are lethal by day 9.5 of embryonic development (E9.5). Ptip-/- embryos assessed at 
E7.5 are smaller than wild-type embryos but progress to S phase of the cell cycle at the same 
time as the wild-type embryos. The Ptip-/- ES cells have significant DNA damage prior to DNA 
replication, however, there is no significant increase in apoptosis as compared to the wild-type 
cells indicating a defect in the DNA repair machinery [234]. By day E8.5, the Ptip-/- embryos 
were arrested in G2 and even though some aspects of gastrulation had occurred, the embryos 
were largely morphologically disorganized accompanied by widespread apoptosis leading to 
embryonic lethality by day E9.5 [234]. Mutants of other important DNA damage response genes 
such as ATR/Chk1 [235-238] and BRCA1 [101,239] are similarly embryonic lethal at E7.5 and 
E6.5, respectively.  
 Human cells or mouse cells depleted of PAXIP1 and treated with IR are hypersensitive to 
double-stranded breaks (DSBs) [64,222,234]. This suggests that PAXIP1 plays a role in 
maintenance of genomic stability by promoting repair. A PTIP-deficient chicken B cell line, 
DT40 was used to demonstrate the role of PAXIP1 in homologous recombination (HR) [240], a 
DNA damage repair process that requires a sister chromatid or homologous chromosome to 
promote repair. The HR repair mechanism is dominant in S and G2 phases of the cell cycle 
[241]. PTIP-/-/- cells show genomic instability as indicated by the slower growth rate, increased 
spontaneous γH2AX foci formation and greater apoptosis in PTIP-deficient cells compared to 
the wild-type DT40 cells [240]. A DNA-damaging agent, camptothecin (CPT, a topoisomerase I 
inhibitor) was applied to the cells, as CPT induced-damage is primarily repaired by HR [242-
244]. PTIP-/-/- cells were shown to be hypersensitive to CPT but not to another DNA-damaging 
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agent, etoposide [240]. Etoposide induced damage is primarily repaired by another DNA-damage 
repair mechanism called non-homologous end joining (NHEJ), that relies on the re-ligation of 
damaged DNA ends primarily in G1 phase of the cell cycle [245]. This may be due to the fact 
that PTIP-/-/- cells have impaired HR initiation and therefore, the cells now solely rely on NHEJ 
for DNA repair leading to etoposide resistance. PAXIP1 has also shown to bind to the 
(MRE11/RAD50/NBS1) MRN complex and BLM (Bloom Syndrome protein) [221,227], both 
important proteins in early DNA damage response and repair. This implicates PAXIP1 as being 
important in HR. It has recently been illustrated that PAXIP1 is required for 53BP1-dependent 
HR in BRCA1-deficient cells and that PAXIP1 may turn out to be a factor in resistance of 
BRCA1-deficient tumors to PARP inhibitor therapy [73].  
In contrast, another study with Paxip1-/- thymocytes in mice indicates that PAXIP1 may 
play a role in NHEJ. Chromatin immunoprecipitation (ChIP) analysis of regions that PAXIP1 
binds demonstrated that PAXIP1 binds to promoters of NHEJ proteins such as DNA-PKcs, 
XRCC4 and Ku80. There was however, no difference between the expression of these NHEJ 
proteins in Paxip1-/- and wild-type thymocytes. Therefore, PAXIP1 is recruited to the sites of 
DSB repair but is not directly involved in the regulation of NHEJ proteins [246]. However, 
PAXIP1 and RIF1, a protein important for class switch recombination (CSR) co-ordinate for 
effective NHEJ [73]. PAXIP1 is also known to play a role in the polyubiquitination of PCNA 
(proliferating cell nuclear antigen). Modification of PCNAs is required for effective functioning 
of DNA polymerases at stalled replication forks [247]. PAXIP1 depletion in Xenopus and human 
cells leads to a marked decrease in Lys-63 polyubiquinated PCNA levels in response to stalled 
replication forks and reduces the lesion-bypass factors recruited to the chromatin [248]. 
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PAXIP1 Regulates Histone Methylation. Post-translational modifications of histones 
are widely known to play an important role in epigenetic regulation of gene expression and 
transcription [249]. Some of the histone modifications important for chromatin remodeling and 
transcriptional regulation are phosphorylation, acetylation, ubiquitylation and methylation [250]. 
Histone methylation can occur on three basic residues i.e. covalent modifications can occur on 
lysine, arginine or histidine residues [251-253]. Methylation of lysine residues is the most 
studied form of histone methylation and it has been shown that lysines can be monomethylated, 
dimethylated or trimethylated [254]. Specific histone methylations are considered markers for 
recruitment of histone complexes and in turn, epigenetically controlling gene transcription and 
expression [255]. Lysine methylation can act as both an activator and repressor of transcription. 
Methylation at K27 of histone H3 or di/trimethylations of histone H3 at K4 lead to gene 
repression or activation, respectively [256]. The lysine residues that are known methylation sites 
are K4, K9, K27, K36 and K79 on histone H3 and K20 and K26 on H4 and H1, respectively 
[255,257].   
The SET domain (Su(var), Enhancer of zeste, Trithorax) superfamily of proteins are 
protein lysine methyltransferases that methylate several different lysine residues on various 
histones for e.g. K9 or K27 on histone H3. The SET domain superfamily consists of seven main 
families of proteins [255]. The SET1 family is one of the important SET-domain families, 
members of which methylate histone H3 at K4. The SET1 family members consist of human 
SET1, Saccharomyces cerevisiae protein Set1, Drosophila TRR (trithorax-related) and Trithorax 
(TRX) proteins and the MLL (Mixed-lineage leukemia) protein group [224]. SET1 family 
members in human cells are a part of multiprotein complexes. The MLL family protein complex 
is the best studied of the SET1 family members and consists of members such as SET1, MLL1, 
	  	   46 
MLL2, MLL3 and MLL4 that impart the enzymatic activity to the complex. SET domain-
containing MLL family proteins associate with the core complex containing WDR5, RbBP5 and 
ASH2 [258]. Besides these shared core proteins, SET1-like complexes in human cells also 
associate with some unique proteins. PAXIP1 is one of these unique proteins that bind to the 
SET1 protein complex.  
PAXIP1 binds to the MLL2 (ALR) complex [224] and another histone methyltransferase 
(HMT) complex, the COMPASS-like complex containing ASH2L, RBBP5, WDR5, hDPY-30, 
NCOA6, MLL3, MLL4, and PA1 [221]. This histone methylation complex containing PAXIP1 
is different from the PAXIP1 complex containing TP53BP1, MRN and BLM DDR proteins 
indicating that the two functions of PAXIP1 may be independent of each other [221,224]. 
Another protein Pituitary homeobox 2 (PITX2), a transcription factor known to be downstream 
of the Wnt signaling pathway has been shown to bind the PAXIP1-containing MLL4 HMT 
complex [259]. The presence of PAXIP1 in these HMT complexes is important for the assembly 
of these complexes [221] and has also been shown to play a role in the methylation of a PAX2 
DNA recognition sequence at its H3K4 methylation site [227]. PAX2 directly binds to PAXIP1 
[218] bringing PAXIP1 to the PAX2-response elements. This leads to the PAXIP1-containing 
HMT complexes such as Ash2L, MLL2, Rbbp5 to bind the PRS4 PAX2 binding region. Ptip-
null mouse embryos or loss of PAXIP1 in human tissues leads to developmentally arrested and 
disorganized embryos that are ultimately lethal in early stages of embryonic development [234]. 
PTIP-/- embryos show reduced expression of H3K4 di- and tri-methylation. However, DAPI-
staining the cells from these embryos exhibited intact and visible nucleoli. This suggests that 
PAXIP1 is required for sustenance of histone methylation marks during development. PtiploxP/loxP 
embryos were viable and at E17.5, high H3K4 levels were observed in the spinal cord. 
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Conditional deletion of Ptip from the developing spinal cords of the PtiploxP/loxP embryos resulted 
in a decrease in H3K4 methylation specific to the spinal cord [227]. The same Cre-LoxP system 
when used to deplete Ptip in the renal medulla of mice results in decreased osmotolerance and 
other important renal functions. PAX2, the PAXIP1 binding protein has a similar function in 
renal development and functioning [260]. Therefore, the PAX2 and PAXIP1 interaction is 
crucial for the assembly and function of HMT complexes and in turn, transcription.   
H3K27 and H3K4 methylation of regulatory genes is essential for embryonic stem (ES) 
pluripotency [261,262]. Ptip-/- ES cells differentiate spontaneously in culture whereas wild-type 
ES cells can remain pluripotent in culture. Oct4, an important transcription factor in stem cell 
development and pluripotency [263] and H3K4 methylation levels are reduced in Ptip-/- ES cells 
[264]. Similar studies in mouse embryonic cells also indicate that Ptip-/- mice exhibit a loss of 
adipocyte differentiation [265], chronic glomerular disease [266] and reduced cardiomyocyte 
development [267] due to lower H3K4 methylation levels in the targeted tissues of these mice. 
In summary, PAXIP1 in an important epigenetic regulator of transcription and is required for 
development and maintenance of embryonic viability and in tissue differentiation.  
 
 The Role of PAXIP1 in the Immune System. V(D)J recombination is a process of 
somatic recombination employed to generate a diverse repertoire of antigen receptors on 
lymphocytes. This recombination process occurs exclusively in T and B cell lymphocytes. In 
germline DNA, recombination-activating genes 1/2 (RAG1/2) bind the recombination signal 
sequences (RSS) and initiate the cleavage at variable (V), diversity (D) and joining (J) loci of the 
T and B-cell receptor genes. The double-stranded break (DSB) created at the cleavage site is 
consequently, repaired by non-homologous end joining (NHEJ) [268]. In developing B-cells, the 
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isotype or antibody function is determined by the constant heavy chain (CH) region. This region 
is surrounded by immunoglobulin (Ig) receptors. Class switch recombination (CSR) is a process 
that results in the switch of the Ig receptors in naïve B cells, such as from IgM to IgD. CSR 
occurs using end-joining ligation instead of homologous recombination. During CSR, activation-
induced cytidine deaminase (AID) enzyme helps in base excision repair and is also needed for 
γH2AX foci formation at DSB site [269]. The recombined IgH locus requires TP53BP1 and 
other NHEJ proteins for joining and DNA repair [270].  
As PAXIP1 has been known to be involved in both histone methylation and DNA 
damage repair, both processes required for CSR, it was further studied to identify its role in B-
cell development. In a study by Daniel et al., Paxipfl/fl mice were crossed with CD19-cre mice to 
generate B-cell specific PAXIP1 knockout mice. It was observed that PaxipΔ/Δ B cells 
proliferated normally and PAXIP1 regulated H4K3 trimethylation (H4K3me3) in selective 
regions in lipopolysaccharide (LPS)-activated B cells. Specifically, Igh-γ2b and Igh-γ3 switch 
regions had decreased histone methylation in Paxip-deficient B cells [271]. H3K4me3 sites are 
found 7kb downstram of Igh switch region in contrast with transcription start sites (TSS) where 
they are found to accumulate within a 2kb distance [272]. Measuring the Igh switch region 
transcripts indicated that IgG CSR was impaired in PaxipΔ/Δ B cells. B cells depleted of PAXIP1 
also had impaired H3K4me2/3, histone acetylation and Pol II association at Igh switch regions. 
This is due to the binding of PAXIP1 to HMT complexes near TSS of specific Ighγ genes. 
Independent of the role of PAXIP1 in transcription of the Igh locus in B cells, it was shown that 
DNA repair after CSR requires PAXIP1. The recruitment of PAXIP1 at the CSR-associated 
break sites is independent of AID activity and as PAXIP1 is known to bind H2AX and RNF8, 
this complex may be responsible for efficient repair of class switch DNA breaks [271]. It has 
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also been demonstrated that PAXIP1 is recruited to the DNA binding site of Pax5, an important 
protein in B-cell development. In PAXIP1-depleted B cells, promoter binding by Pax5 and long-
range chromatin interactions were reduced. Therefore, PAXIP1 interaction with Pax5 is 
important for chromatin looping and eventually, for CSR during B-cell development [273].  
In thymocyte development, PAXIP1 regulates the germline transcription of the T-Cell 
receptor (TCR) loci and also helps in repair of DNA damage. PAXIP1 is important for this 
process as it controls RAG mediated DNA damage and repair during the V(D)J recombination of 
CD4+ CD8+ double positive (DP) thymocytes. T cell receptor alpha (Tcra) breaks accumulate in 
thymocytes with no PAXIP1. PAXIP1 is also necessary for the transcriptional activation of 
sphingosine-1-phosphate receptor (S1pr1), which leads to the development of single positive 
(SP) αβT cells and their release from the thymus. Natural killer T cell development is also 
affected by loss of PAXIP1 in cells.  This confirms that the role of PAXIP1 as a transcriptional 
regulator and DNA damage repair protein work in tandem for mature thymocyte development 
and thymic export [246].  
 
PAXIP1 and DNA Damage Signaling. PAXIP1 is known to be involved in DNA 
damage signaling through its BRCT-domains [16,64]. The C-terminal BRCT was shown to bind 
peptides phosphorylated at the S/T-Q motifs by ATM/ATR kinases [16]. It has also been shown 
that PAXIP1 binds another BRCT-containing protein, 53BP1, in response to IR, in an ATM-
dependent manner. However, the translocation of 53BP1 and PAXIP1 to the site of damage to 
form IR-induced foci (IRIF) is not ATM-dependent. To bind 53BP1 post IR, both the C-terminal 
tBRCT domains pair C1 and C2 of PAXIP1 are required [64] and 53BP1 needs to be 
phosphorylated at its Ser25 site by ATM [233]. Phosphorylation of Ser15 and Ser20 of p53 
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mediated by IR is reduced in PAXIP1-depleted cells. The cell viability of PAXIP1-depleted cells 
is not reduced even though PAXIP1 has been shown to be an essential protein in embryonic 
development indicating that PAXIP1 is essential for development but not for growth in somatic 
cells [64]. However, PAXIP1 is required in cells for survival post IR [234]. PAXIP1 localizes to 
sites of DNA damage with γH2AX, 53BP1 and the MRN complex suggesting its role in early 
DDR [64,222,228,233,274]. In the DDR pathway, PAXIP1 was found to be upstream of 53BP1 
and downstream of γH2AX, MDC1 and an E3 ubiquitin ligase, RNF8. However, PAXIP1 was 
not directly ubiquitinated by RNF8 indicating that the interaction is indirect or that ubiquitination 
is not involved in this interaction. Chromatin remodeling by the PAXIP1-53BP1 interaction is 
important for the phosphorylation of an important DDR protein, SMC1 by ATM. This indicates 
PAXIP1 has a role in detection and signaling of chromatin lesions [222,274]. PAXIP1 foci 
formation occurs not only as a response to IR but also other DNA-damaging agents such as 
camptothecin (CPT), etoposide (VP16) and mitomycin C (MMC) [222]. Overall, PAXIP1 is an 
essential protein in the DDR, however, its role in the DDR process and its dynamics have not 
been very well defined. In this dissertation, we discuss some novel roles of PAXIP1 in response 
to DNA-damaging agents such as IR and cisplatin.  
 
PAXIP1 Involvement in the Cell Cycle. In murine studies, mouse embryonic fibroblasts 
(MEFs) that were PTIP-null were evaluated for their progression through the cell cycle. 
Phosphorylated histone H3 (pHH3) levels, a marker of chromatin condensation during mitotic 
progression was tested in these MEFs. It was shown the PTIP-/- MEFs did not have pHH3 
expression indicating that PTIP-null cells do not progress from S-phase to mitosis [234]. Studies 
in Schizosaccharomyces pombe showed that Brc1, a 6-­‐BRCT-­‐containing protein structurally 
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similar to PAXIP1 is essential for DNA damage repair during S phase [275]. This has been 
confirmed in mammalian cells as it was shown that PAXIP1-deficient cells had a decrease in 
their ability to activate the DNA damage-induced intra-S-phase checkpoint [274]. Therefore, 
PAXIP1 plays a role in checkpoint activation post DNA damage and in the G2/M checkpoint; 
however, its exact role in these processes has not been elucidated. This dissertation discusses a 
novel role of PAXIP1 in the regulation of the cell cycle and its effect on cancer therapy.  	  
WEE1: Structure and Functions 
 
The Structure of WEE1. The cell cycle in eukaryotic cells is an intricately controlled 
temporally and spatially by cyclin-dependent kinases (Cdks). These kinases are activated and 
deactivated by a set of kinases and phosphatases at various stages of the cell cycle. WEE1 kinase 
is at the 11p15.4 in the genome and is a key regulator of the mitotic checkpoint [276]. WEE1 is 
an atypical tyrosine kinase that structurally resembles serine/threonine kinases [277]. Wee1 was 
first discovered in fission yeast, Schizosaccharomyces pombe. It was shown that wee1 expression 
was directly correlated with cell size that is in wee1+ cells, mitosis was delayed until cells had 
reached a critical size. Wee1 delays the entry of cells into mitosis by phosphorylating and 
inhibiting a promoter of mitotic entry, the Cdk1 kinase (known as cdc2+ in fission yeast). [278-
281]. In humans, two WEE1 kinases have been characterized: WEE1A and WEE1B [282]. 
WEE1B is found primarily in testis and oocytes [282,283] and WEE1A is the somatic WEE1 
kinase that will be discussed in detail here.  
WEE1A (WEE1) kinase is a 646 amino acid protein and consists of three domains, a N-
terminal domain (amino acids 1-291), a kinase domain (amino acids 291-575) and a C-terminal 
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domain (amino acids 575-646) (Figure 11). The phosphorylations at serines 53 and 123 at the N-
terminal domain of WEE1 are required for its destruction and turnover at appropriate times in the 
cell cycle [284,285]. The kinase domain besides being required for phosphorylating WEE1 
substrates has also been shown to be important for signaling for WEE1 degradation [286]. WEE1 
structure also contains three PEST (Proline (P), glutamic acid (E), Serine (S), Threonine (T)) 
regions that are important for proteolysis [277,284,287]. Phosphorylation at the S642 site of 
WEE1 by AKT regulates the binding to the 14-3-3 protein for cytoplasmic localization [288].  
 
 
 
 
 
 
 
Figure 11. WEE1 structure. Schematic of WEE1 and its domains, the protein has an N-
terminal domain, a central kinase domain and a C-terminal domain. Adapted from [277]. 
 
The main substrate of WEE1 is CDK1, which is phosphorylated on its Tyrosine 15 (Y15) 
site by the mitotic kinase [284,289-292]. However, WEE1 is considered an atypical tyrosine 
kinase as it is not structurally similar to the other kinases in the tyrosine kinase family [293] and 
likens more with the serine/threonine family of kinases [277,278]. During G2, another kinase, 
Myt1 phosphorylates CDK1 at its Threonine 14 (T14) site, along with the Y15 phosphorylation 
by WEE1. This keeps CDK1 inactivated in the S and G2 phases of the cell cycle [294]. 
Therefore, Myt1 and WEE1 belong to their own family of kinases [295]. Two sites on WEE1, 
Tyr 295 and Tyr 362 are considered autophosphorylation sites promoting WEE1 activity 
[288,296].  
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Role of WEE1 in Mammalian Development and Genomic Stability. In drosophila and 
yeast, Wee1 is required for mitotic regulation of cells [278,297]. In murine models, Wee1-/- mice 
died during embryonic development. The embryos were lethal at embryonic day 3.5 (E3.5) at 
their blastocyst stage. The Wee1-/- embryos were defective in inducing the G2/M checkpoint 
when treated with γ-irradiation and subsequently, underwent apoptosis [298]. Budding yeast 
homolog of Wee1, Swe1 has also been shown to be required for mitotic regulation and cell size 
control [299,300]. However, some of these functions of WEE1 cannot be explained just by 
phosphorylation of CDK1 by WEE1 alone. WEE1 knockout mice have several defects in 
addition to mitotic deregulation.  
 In a tamoxifen inducible mouse embryonic fibroblast (MEF) line (Wee1Co/−;Tm-Cre), it 
was shown that mitosis developed prematurely [301]. However, in addition to early mitotic 
entry, these MEFs with depleted Wee1 displayed centromosomal defects. It has been 
demonstrated that WEE1 binds the anaphase-promoting complex (APC/C), which is an E3 
ubiquitin ligase important for turnover and degradation of cell cycle proteins [302]. The APC/C, 
through its co-activators, CDH1 and CDC20 has a crucial role in mitotic progression and 
downregulation of the APC/C members leads to genomic instability [303-305]. Wee1 deficiency 
in MEFs leads to increased activity of the APC/C complex, which constitutes a negative-
feedback system required for maintenance of genomic integrity and mitotic regulation [302]. 
APC/C was also shown to bind PAXIP1 in the study in our lab by Woods et al., indicating that 
there may be a correlation between the roles of PAXIP1, WEE1 and APC/C in mitotic 
progression [22].  
 WEE1 plays an important role in maintenance of DNA damage induced genomic 
stability. It has been demonstrated that depletion of WEE1 in mammalian cells leads to foci 
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formation by DNA damage proteins such as γH2AX, 53BP1 or MDC1 akin to treating the cells 
with UV or IR. Proteins from the ATR pathway, such as RPA, Rad9 and TopBP1, form similar 
foci due to WEE1 depletion [306]. Downregulation of WEE1 also leads to a decrease in CHK1 
levels, which has been shown to increase γH2AX levels in S-phase cells [307]. WEE1 was also 
indicated to be a regulator of DNA replication. Depletion of WEE1 in the presence of DNA 
damage leads to stalled replication forks, accumulation of cells in S phase and amplification of 
γH2AX phosphorylation. WEE1 controls DNA replication by interaction with the Mus81-Eme1 
endonuclease, which cleaves branched replication forks and Holliday junctions [306,308]. WEE1 
inhibition also leads to decrease in the nucleotide pool during replication firing and 
consequently, decreased fork speeds [309]. WEE1 has also been shown to phosphorylate histone 
H2B at its Tyr37 site at the end of S phase, just as CDK1, its other substrate is dephosphorylated 
by CDC25, indicating that the genomic stability functions of WEE1 are tightly regulated with its 
cell cycle functions [310]. This demonstrates that WEE1 plays an important role in initiation and 
stabilization of replication forks during DNA replication and maintenance of genomic stability 
during the DDR. 
 
  Cycle Regulation by WEE1. WEE1 and its kinase family member, Myt1 phosphorylate 
the CDK1/Cyclin B complex at the tyrosine 15 (Y15) and threonine 14 (T14) sites, respectively 
[290,292,294,311-313]. 
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Figure 12. Role of WEE1 and CDK1 in the cell cycle. In the normal cell growth and division 
process, WEE1 and Myt1 phosphorylate CDK1 until the cells are ready to progress to mitosis. 
Cdc25 dephosphorylates CDK1 when the cells are ready to transition from G2 to M. During 
DNA damage, CDK1 is inactivated by WEE1 until the damage is repaired and post DNA repair, 
WEE1 is phosphorylated and degraded by proteosomal degradation. Adapted from [314]. 
 
This inactivates CDK1 until the end of G2 phase of the cell cycle when the cells are 
ready to progress to mitosis at which point CDK1 is dephosphorylated and activated by CDC25 
phosphatase (Figure 12) [315,316]. 
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Interphase. WEE1 is predominantly a nuclear protein, however, it is also 
observed in the cytoplasm of resting cells [317,318]. The localization and degradation of WEE1 
during the G1, S and G2 phases of the cell cycle is controlled by its binding to the 14-3-3 β 
protein [319].  
The binding of WEE1 to 14-3-3 is regulated by the phosphorylation of WEE1 by AKT1 
at serine642 (S642), which lies in its C-terminal domain. The S642 phosphorylation is important 
for inducing cell cycle delay before cells are ready to enter mitosis [320,321]. The S642 
phosphorylation by CHK1 or AKT also causes the cytoplasmic localization of WEE1 during the 
S and G2 phases leading to progression of G2/M [288,320]. WEE1 is also autophosphorylated at 
multiple sites [322]. WEE1 is positively regulated during interphase by the PP2A phosphatase 
and Hsp90 heatshock protein [323,324]. During S-phase, due to H2B phosphorylation and 
Mus81 binding, WEE1 plays a role in DNA replication before cells proceed to the G2/M 
checkpoint.  
 
WEE1 at the G2/M transition. In late G2, when the cells are ready to proceed to 
mitosis, WEE1 kinase is downregulated and CDK1 is dephosphorylated and activated by Cdc25. 
Cdc25 is in turn phosphorylated by CDK1 and this amplifies the feedback loop between the 
CDK1 kinase and the Cdc25 phosphatase leading to rapid progression of mitosis [322]. CDK1-
dependent phosphorylation also creates a docking site for another mitotic kinase, Polo-like 
kinase 1 (Plk1) [325]. Plk1 and CDK1 phosphorylate WEE1 on serines 53 and 123, respectively. 
This creates a phosphodegron (signal for degradation) motif (DpSGXXpS) on Wee1, which is 
required for binding the F-box protein β-TrCP [285]. β-TrCP is a ubiquitin ligase that rapidly 
poly-ubiquitinylates and leads to proteasomal degradation of WEE1 [326]. Plk1 also 
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phosphorylates Myt1 and Cdc25, leading to activation of the phosphatase and localization to the 
nucleus [327,328].	  Due to degradation, the protein levels of WEE1 in mitotic cells are ten times 
lower than cells in G2 [284]. This balance is important for rapid transition from G2 to mitosis. 
Once the cell division has occurred; WEE1 levels in interphase are maintained for the new cell 
cycle. Therefore, CDK1, Cdc25, Plk1, Myt1 and WEE1 are important kinases that work in 
coordination for the G2/M transition to occur. 	  
 
Nucleocytoplasmic shuttling and subcellular localization. The temporal 
regulation of CDK1 and WEE1 during the different phases of the cell cycle is controlled by the 
intracellular localization of the two kinases. Immunofluorescence experiments in HeLa and 
IMR90 fibroblast cells showed the WEE1 expression varied based on confluence of the cells in 
culture. In the sub-confluent fibroblasts, the WEE1 expression was diffused and primarily in the 
nucleus. On the other hand, in confluent HeLa cells, the majority of WEE1 was in the cytoplasm. 
In exponentially growing cells, WEE1 was found almost exclusively in the nucleus. This 
indicates that WEE1 localization is controlled by the cell cycle and cell density [317]. 
 WEE1 nuclear dots appear in the cell between late G1 and S phase, prior to DNA 
synthesis. In late G2, WEE1 suppresses CDK1 around the spindle pole body (SPB) and WEE1 
phosphorylates CDK1 in the nucleus and on the SPB [329]. During mitosis, WEE1 relocates to 
the cytoplasm, with a fraction of it remaining in the nucleus bound to chromatin. During cell 
division, WEE1 is detected in division plane and nuclei of the daughter cells. The other 
components of cell cycle regulation such as Cdc25, CDK1, Plk1 and Myt1 also undergo 
nucleocytoplasmic shuttling at various stages of the cell cycle to control the transition from one 
phase to another [317,328]. 
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WEE1 as a therapeutic target. Targeting kinases primarily using ATP mimetics 
is a form of therapy that has been employed in many cancer types. A large majority of kinases, 
mostly tyrosine kinases are overexpressed, mutated or dysregulated in cancers. This makes them 
ideal targets to impart the most benefit and to overcome resistance to standard chemotherapy in 
some cases [330]. Increased WEE1 expression has been found in many different cancers such as 
hepatocellular carcinoma, breast cancers, mantle cell lymphoma, sarcoma and glioblastoma 
among others [331-336]. Standard DNA damaging agents such as IR, platinum compounds and 
topoisomerase agents have been used in many cancers [337,338]. However, cells develop 
resistance to these therapies as they arrest to repair the DNA damage caused by these agents 
[163,339]. Therefore, targeting cell cycle proteins can help overcome the resistance to DNA-
damaging therapies and help in selectively targeting tumor cells over normal cells [211,340].  
 p53 is a protein that regulates the G1 to S transition. Tumors treated with DNA-damaging agents 
arrest in G1, however, p53 is frequently mutated in tumors. Therefore, tumors rely on the G2/M 
checkpoint for arrest post chemotherapeutic treatment [339,340]. WEE1 is a major regulator of 
the G2/M checkpoint and therefore, its inhibition sensitizes tumor cells to DNA damage 
[341,342]. Multiple pharmacological inhibitors of WEE1 kinase activity have been developed 
[343,344]. The most potent and selective inhibitor of WEE1 is AZD1775 (formerly, MK-1775). 
It is a pyrazole-pyrimidine derivative and has an IC50 of 5 nmol/L for WEE1. AZD1775 also has 
other kinase targets, such as YES1 at 14 nmol/L and >100-fold less selective towards Myt1. p53-
mutant colon cancer cells that were treated with AZD1775 and gemcitabine had decreased Tyr15 
phosphorylation of CDK1 and were shown to abrogate the gemcitabine-induced cell cycle arrest 
[212]. Similar results were reported in multiple cancer cell lines and in combination with DNA 
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damaging agents such as 5-fluorouracil (5-FU), pemetrexed, doxorubicin and camptothecin 
[345,346]. It was shown in breast cancer cell lines that WEE1 levels do not correlate with 
response to therapy presenting the need for other biomarkers to predict the tumors that respond 
to WEE1 inhibition [346,347]. Besides abrogation of the G2/M checkpoint, the WEE1 inhibitor, 
AZD1775, has also been shown to force S phase arrested cells directly into mitosis before DNA 
synthesis can be completed. This resulted in abnormal mitoses leading to micronuclei formation 
and apoptosis [348].  
WEE1 inhibitors have shown to abrogate the G2 checkpoint in multiple tumor cell lines 
[342,349,350]. In cervical cancer lines, WEE1 inhibition using shRNA in combination with 
adriamycin treatment led to apoptosis in cancer cell lines but not in epithelial cells [341]. 
AZD1775 in combination with gemcitabine, carboplatin or cisplatin in p53-deficient colon, lung 
and ovarian cells was more effective than in p53-wild type cells [351]. In multiple subtypes of 
breast cancer, estrogen receptor positive, Her2-amplified and triple negative, treatment with 
WEE1 inhibitor alone showed increased DNA damage, apoptosis and decrease in cell viability 
[346]. In glioblastoma cell lines, silencing of WEE1 or treatment with WEE1 inhibitors in 
combination with temozolomide demonstrated increased cell death. Similar cell death was not 
seen in fibroblasts and astrocytes treated with the same combination. p53 status did not have an 
effect on the outcome of the treatment in the glioblastoma cell lines [335]. Recently multiple 
agents such as panobinostat, HDAC inhibitors, PARP inhibitors and radiotherapy have been 
shown to be effective in combination with AZD1775 [334,352-355]. 
In vivo, xenograft models demonstrated that AZD1775 treatment as monotherapy or in 
combination with other agents, leads to tumor reduction. In the initial studies, nude rats bearing 
colon cancer xenografts were administered a combination of AZD1775 and gemcitabine, which 
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showed reduced tumor growth with no toxicity [212]. Similar results have been demonstrated in 
xenograft models of other cancers such as pancreatic cancer [356], glioblastoma [334,335], 
sarcoma [336] and head and neck cancer [357], to name a few. Similar to what was observed in 
vitro, in all these cancer types, monotherapy was found to have a modest effect as compared to 
combination therapy with cisplatin, gemcitabine, IR and other DNA-damaging agents. It has also 
been demonstrated that having low levels of Myt1, another mitotic kinase, correlates with better 
response to WEE1 inhibitor therapy [358]. Overall, both in vitro and in vivo, WEE1 inhibitors 
when combined with DNA-damaging agents lead to cell death due to mitotic catastrophe and 
with no adverse effects being observed in animal models, these inhibitors are ready to be tested 
in the clinic [347].  
Clinical studies are currently underway using AZD1775 in multiple cancer types. The 
first phase I study in advanced solid cancers (NCT00648648) with 91 patients tested AZD1775 
as a monotherapy and in combination with gemcitabine, carboplatin or cisplatin. Adverse effects 
such as nausea, hematologic events such as myelosuppression and fatigue were observed in 
~20% of the patients. [347] Over 15 phase I and II clinical trials are currently underway to test 
AZD1775 combination therapy in solid tumors and in lymphoma (https://clinicaltrials.gov). 
Combination of CHK1 and Hsp90 inhibitors with AZD1775 are also being tested in a clinical 
setting [359-361].   
The current candidate biomarkers of AZD1775 therapy are pY15-CDK1 levels, pHH3 
levels to check the mitotic population and a gene signature shown to correlate with WEE1 
sensitivity. None of these have been extensively validated in a clinical setting [212,362]. 
Therefore, there is a need for biomarkers to find the subset of patients that could most benefit 
from WEE1 inhibitor combination therapy.  
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Lung Cancer 
Lung cancer broadly encompasses tumor formation in lung tissues, mainly the respiratory 
epithelium [363]. Cigarette smoking is attributed to be the leading cause of lung cancer but there 
are also other causes such as occupational carcinogens such as asbestos and environmental 
radiation [364]. In the US, at 14%, lung cancer is the second most diagnosed cancer of all the 
cancers diagnosed and at 28%, the leading cause of cancer deaths, in both men and women. The 
5-year survival rate for lung cancer is 15.6% [365]. Therefore, there is a great need for therapies 
to increase survival rates in lung cancer.  
 
Histological Subtypes. Lung cancer is largely divided into two main types – non-small 
cell lung cancer (NSCLC) and small cell lung cancer (SCLC). NSCLC is further divided into 
adenocarcinoma, squamous cell carcinoma and large-cell carcinoma [363]. All of the histological 
subtypes are found in smokers; however, squamous carcinomas are found mainly in heavy 
smokers. Due to change in smoking patterns, adenocarcinomas are the largest percentage of lung 
tumors diagnosed now as opposed to squamous carcinomas in the early 20th century [366,367]. 
The histological distinction is based on pathological evaluation. In women, adenocarcinoma is 
more frequently diagnosed as compared to squamous cell tumors and the opposite is observed in 
men [368]. Prior to the discovery of mutations that can be targeted in different subtypes of 
NSCLC, treatment did not vary based on histology. First-line therapy for patients with NSCLC 
remained cytotoxic therapies such as cisplatin, carboplatin, gemcitabine or taxanes [363,368].  
However, with the advent of tyrosine kinase inhibitors (TKIs) to treat patients with 
epidermal growth factor receptor (EGFR) mutations in their tumors, the landscape of lung cancer 
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classification changed [369]. Many different molecular markers and their corresponding 
inhibitors were identified following EGFR and these will be discussed here. 
 
Current Treatment Modalities. Even though chemotherapeutic agents such as cisplatin, 
vinblastine and pemetrexed are the mainstay in lung cancer treatment [363], lung tumors are now 
divided by their histology as different genomic markers have been shown to determine the 
biology in the various subtypes. Anti-EGFR inhibitors such as gefitinib, erlotinib and cetuximab 
target tumors with constitutively active EGFR inhibiting autophosphorylation of the kinase and 
its downstream targets [370]. These mutations are primarily found in adenocarcinomas and have 
greatly increased the prognosis of patients with EGFR-mutant lung adenocarcinomas [371].  
Another set of mutations that are found in 4-5% of NSCLCs is the EML4 (echinoderm 
microtubule-associated protein-like 4)–ALK (anaplastic lymphoma kinase) fusion [372]. 
Crizotinib has been approved for patients with these ALK fusions and is shown to have a better 
progression-free survival compared to standard chemotherapy [373]. However, resistance to both 
these EGFR and ALK inhibitors is in many patients due to secondary mutations in the genes, 
which prevent the binding of inhibitors to the ATP binding site [374-376]. HER2, AKT, KRAS, 
MET and ROS are some of the other molecular drivers that have been identified in lung cancer 
[377-380]. As resistance to these inhibitors develops quickly, there is a constant need for 
therapies to overcome this resistance and to improve survival rates. Therefore, in this 
dissertation, we perform a screen to identify inhibitors that can sensitize chemotherapy in 
different histological subtypes of lung cancer.  
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Chapter Four. Material and Methods 
 
 
 
Cell Lines and Transfections 
Human lung cancer cell lines A549, ADLC-5M2, NCI-H23, NCI-H157, NCI-H322, NCI-
H441, NCI-H522, NCI-H596, NCI-H1299, NCI-H1355, NCI-H1395, NCI-H1437, NCI-H1648, 
NCI-H1666, NCI-H2170, NCI-H2347, NCI-H3122, and PC9 (short names used throughout) 
were cultured in RPMI-1640 medium (Life Technologies) and HEK 293FT (Invitrogen) cells in 
Dulbecco Modified Eagle Medium (DMEM) (Gibco) at 37°C in 5% CO2. Media were 
supplemented with 10% FBS (Fisher Scientific), 1% penicillin-streptomycin (Invitrogen) and 
0.5% Amphotericin-B (Fisher Scientific). AALE (tracheobronchial epithelial cells) were grown 
in Bronchial Epithelial Growth Medium containing growth supplement (Lonza). All cell lines 
have been maintained in a central repository at the Moffitt Cancer Center since 2008. All cell 
lines had been authenticated by STR analysis (ACTG Inc, Wheeling, IL) as of September 2010, 
and all cells had been routinely tested and were negative for mycoplasma (PlasmoTest, 
InvivoGen, San Diego, CA). 
All cell lines were transfected using Lipofectamine 2000 (Invitrogen) using the 
manufacturer’s protocol with the exception of 293FT cells which were transfected using 50mM 
calcium phosphate [381]. shRNA contructs in pLK0.1 targeting PAXIP1, WEE1 and a 
scrambled control were purchased from Open Biosystems. AZD1775 (MK-1775) (Selleck 
Biochem) and cisplatin (Sigma-Aldrich) were added directly to the culture medium unless 
otherwise specified.  
	  	   64 
Cloning Information for Constructs 
The tandem BRCTs of PAXIP1, tBRCT N1 (aa 8-183), tBRCT C1 [amino acids (aa) 
601-779] and tBRCT C2 (aa 866-1069) were individually cloned into the pNTAP vector 
(Agilent). Full-length green fluorescent protein (GFP) was cloned into the pNTAP vector and 
used as a control in all experiments. pNTAP vectors contain tags for a calmodulin binding 
domain (CBP) and streptavidin binding domain (SBP) to detect their expression. Full length 
PAXIP1 was cloned into the FLAG-pCDNA3 vector as described here [64] (Gift from Dr. 
Renato Carvalho). Myc-tagged full length WEE1 in pCMV3-Tag2 vector was obtained as a gift 
from Dr. Nupam Mahajan. To obtain the various domains of WEE1, constructs corresponding to 
aa 1-293 which contains the N-terminal regulatory region (fragment 1), aa 293-569 kinase 
domain (fragment 2), aa 569-646 C-terminal domain (fragment 3) were obtained by PCR using 
full-length WEE1 in pCMV3-Tag2 as template. The following primers containing attb sites are 
5'-GGGGACAAGTTTGTACAAAAAAGCAGGCTCCATGAGCTTCCTGAGCCGACAG-3', 
5'-GGGGACCACTTTGTACAAGAAAGCTGGGTTTACCGGGACTTCATATTGCTTTC-3' 
for fragment 1, 5'-
GGGGACAAGTTTGTACAAAAAAGCAGGCTCCTATACAACAGAATTTCAT-3' and 5'-
GGGGACCACTTTGTACAAGAAAGCTGGGTTTAACAGCAATACTGAATGCT-3' for 
fragment 2, 5'-
GGGGACAAGTTTGTACAAAAAAGCAGGCTCCTCCGCTTCTAGAAAGAGT-3' and 5'-
GGGGACCACTTTGTACAAGAAAGCTGGGTTCAGTATATAGTAAGGCTGAC-3' for 
fragment 3. Gateway recombination cloning was used to clone the PCR products into 
pDONR221 vector followed by the pDEST27 vector with an N-terminal GST fusion (Invitrogen) 
and sequenced for confirmation.   
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Liquid Chromatography-Multiple Reaction Monitoring Mass Spectrometry 
 Mass spectrometry (MS) based assays have been widely used for characterization of 
proteins in both research and clinical settings. Liquid chromatography-multiple reaction 
monitoring (LC-MRM) is a mass spectrometry technique used to quantify multiple proteins from 
a sample mixture [382]. Protein lysate (25µg) from cell lines was fractionated on Bis-Tris gels 
(Criterion XT, Biorad) and visualized with Coomassie Brilliant Blue G-250 (Aldrich). The gel 
was divided into four regions based on molecular weight (>120 kDa; 70-120 kDa; 40-70 kDa; 
20-40 kDa). These regions were excised, resuspended in 1 ml Milli-Q water and shaken for 30 
minutes at room temperature. The gel slices were destained with 50mM ammonium bicarbonate 
and 50% methanol followed by reduction with 2mM tris-carboxyethylphosphine and alkylation 
with 20mM iodoacetamide, washed with 50mM ammonium bicarbonate/50% Methanol prior to 
overnight digestion with trypsin (Promega). The proteolytic peptides were extracted with 50% 
acetonitrile/0.01% trifluoroacetic acid and concentrated using vacuum centrifugation. Peptides 
were resuspended with aqueous 2% acetonitrile with 0.1% formic acid along with their internal 
standards. LC-MRM analysis was performed on a nanoLC interfaced with an electrospray triple 
quadrupole mass spectrometer (Vantage, Thermo) as described [383]. Data were analyzed using 
Skyline 1.3 [384], and peaks were evaluated and normalized using GAPDH to control for 
cellular loading. Mean peak area for three technical replicates was calculated for each cell line. 
The output data from 15 cell lines was then ranked from the highest to the lowest in order of 
their peak areas (protein expression). Representative peptides analyzed for each protein are listed 
in Table 3.  Cell line with the highest expression for a particular kinase was ranked 1 and the cell 
line with the lowest expression was ranked 15 (Figure 13). These scores were then used to 
generate a heat map showing the relative expression of each kinase between the cell lines.  
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Table 3. Peptides for the DNA damage proteins for LC-MRM  
Protein Kinase  Peptide Sequence 
WEE1 GIDSSSVK 
SRPK2 LQEIEELER 
SRPK1 LAAEATEWQR 
MAPK3 NYLQSLPSK 
MAPK1 LFPNADSK 
MAP4K4 TGQLAAIK 
MAP3K1 SESPGVR 
MAP2K2 VSIAVLR 
EIF2AK1 EVALEAQTSR 
DYRK1A VEQEWVAIK 
CSNK2A1 FNDILGR 
CSK2B RPANQFVPR  
CDK9 AANVLITR  
CDK16 SLTLVFEYLDK 
CDK13 TKPLTPSIGAK 
CDK12 GSPVFLPR   
AURKC VYLILEYAPR 
 
Antibodies and Western Blotting 
 Whole cell protein lysates were prepared in RIPA lysis buffer [120mM sodium chloride 
(NaCl), 50mM Tris pH 7.4, 0.5% sodium dodecyl sulfate (SDS), 1% Triton-X, 1mM EDTA, 
protease inhibitors, 4mM PMSF] and other buffers for immunoprecipitation, kinase assays as 
indicated in their respective protocols. For western blot analysis, samples were resolved using 
SDS-PAGE (polyacrylamide gel electrophoresis) and gels were transferred on methanol 
activated PVDF (Polyvinylidene fluoride) membranes (Millipore). PVDF membranes were 
blocked in 5% non-fat milk/TBS-T (0.5% Tween-20 in Tris-buffered saline) for 30 minutes. 
Membranes were incubated in primary antibody in 5% milk/TBS-T overnight at 4°C. 
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Figure 13. Liquid chromatography - multiple reaction monitoring mass spectrometry.  
Coomassie stained SDS-page gel for multiple-reaction monitoring (MRM) – Gels were cut into 
four sections based on protein size to incorporate the seventeen kinases from the PPIN. Peak area 
for each representative peptide for a protein was analyzed by MRM. Liquid chromatography-
Multiple reaction monitoring (LC-MRM) based mass spectrometry was used to quantify the 
expression levels of the seventeen kinases. For each protein, the fifteen cell lines were ranked 
based on their peak areas (expression levels), the highest being 1, the lowest being 15. 
 
 
	  	   68 
 
Membranes were washed three times with TBS-T and incubated with the appropriate 
HRP conjugate for 2 hours at room temperature. Three final washes with TBS-T were performed 
and the blots were incubated with chemiluminescent HRP substrate (ECL) (Millipore) and 
detected using autoradiography film (Denville Scientific). Western blotting was performed using 
antibodies against WEE1 (Cell Signaling), PTIP/PAXIP1 (Bethyl Laboratories), CBP 
(Genscript), pY15-CDK1 (Cell Signaling), CDK1 (Cell Signaling), Pan-phospho-Tyrosine (P-
Tyr-100) (Cell Signaling), glutathione-S-transferase (GST) (GE Healthcare), alpha-tubulin 
(Sigma-Aldrich) and beta-actin (Santa Cruz). For detection, PVDF membranes were incubated 
with their respective horseradish peroxidase conjugated secondary antibodies (Santa Cruz) and 
developed using ECL substrate (Thermo Scientific). For densitometry analysis, ImageJ software 
was used. All the lanes were normalized to their corresponding loading control and then 
quantified as fold change compared to the control lane. α-WEE1 mouse monoclonal antibody 
(Santa Cruz) and α-PAXIP1 (Atlas antibodies, Sigma) were used for immunohistochemistry. 
Anti-phospho-Histone H3 (Ser10, Millipore) and DAPI (NucBlue, Invitrogen) were used for 
flow cytometry.  
 
Immunoprecipitation Assays 
Endogenous immunoprecipitation assays were carried out in CHAPS lysis buffer [0.5% 
CHAPS, 150mM NaCl, 10mM Hepes, pH 7.4, protease and Halt protease and phosphatase 
inhibitor cocktail (Thermo Scientific). 500µg of whole cell lysate was extracted and 5µg of α-
PAXIP1 antibody or 5µg of α-BARD1 antibody were added and immune complexes were 
allowed to form for 1 h at 4°C. 20µl of protein A/G Sepharose beads (Santa Cruz Biotechnology) 
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were added and samples were incubated overnight with rotation at 4°C. The next day the bead-
protein complex was pelleted by centrifugation (5,000 rpm) and supernatant was discarded.  The 
beads were washed three times with the lysis buffer, boiled in Laemmli buffer for 5 min and 
analyzed by western blotting.  
 
Pull-Down and Phosphatase Assays 
 Tandem BRCTs, tBRCT pair N1, pair C1 and pair C2 of PAXIP1 and pNTAP-GFP were 
transfected into 293FT cells using calcium phosphate transfection. Cells were collected and 
incubated in NETN [0.5% Nonidet P-40, 20mM Tris pH 8.0, 50mM NaCl, 50mM NaF, 100µM 
Na3VO4, 1mM DTT, and 50µg/ml PMSF] buffer for 20 minutes at 4°C. Lysate was obtained by 
centrifugation (13,000 rpm) for 5 minutes at 4°C. 20µl of streptavidin beads were added to the 
lysate and incubated overnight at 4°C. After incubation, the beads were washed three times with 
the NETN buffer and boiled in laemmli buffer for 5 minutes and analyzed by western blotting. 
NETN buffer was used as the initial interaction between PAXIP1 and WEE1 using TAP-
purification was detected in NETN buffer, as described here [22].  
For GST-pull down assays, plasmids with GST-tagged WEE1 fragments and the C-
terminal tandem BRCT (tBRCT) of PAXIP1 in pNTAP vector were co-transfected into 293FT 
cells and pull-down assays were performed using streptavidin beads as described above. Samples 
were analyzed by western blotting with antibodies against GST and CBP.  
For phosphatase assays, tBRCT C2 of PAXIP1 and pNTAP-GFP were transfected in 
293FT cells. Lysates were obtained using NETN buffer and incubated with streptavidin beads. 
The beads were washed three times with the buffer and were treated with calf intestinal 
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phosphatase (New England Biolabs) with or without 50mM EDTA for 30 min at 30°C. The 
beads were then washed, boiled in Laemmli buffer and analyzed by western blotting. 
 
Kinase Assays 
 For the in vitro kinase assay, 200ng of purified GST-tagged WEE1 (Invitrogen) and 
100ng of active CDK1 (Millipore) were incubated in the presence or absence of 200ng of 
recombinant PAXIP1 tBRCT C2 in WEE1 kinase assay buffer containing 50mM HEPES (pH 
7.5), 15mM MgCl2, 1mM EGTA, 10% glycerol, 10mM DTT and 0.1mM ATP at 30°C. After 20 
min, the reaction was stopped by boiling in Laemmli buffer. The samples were then run on a 
10% SDS-PAGE gel followed by immunoblotting with α-GST, α-pY15-CDK1 or α-pTyr-100 
antibodies.  
 
Flow Cytometry, Cell Cycle Analysis and Phospho-Histone H3 Staining 
 For phenotypic analysis of H322 lung adenocarcinoma cells, cells were analyzed by flow 
cytometry. For cell cycle analysis and assessment of mitotic index, phospho-Histone H3 staining 
(pHH3) and DAPI staining was used. Cells were plated at 3 X 106 cells per 100mm plate. The 
next day, cells were transfected using Lipofectamine 2000 with full-length FLAG-PAXIP1 or 
pLK0.1 PAXIP1 shRNA along with their empty vector controls. 24 hours post-transfection, cells 
were treated with AZD1775 for 1 h, irradiated (6 Gy) and incubated for another 4 h to analyze 
the early G2/M checkpoint [203]. Cells were harvested with trypsin, washed twice with PBS and 
106 cells were fixed using 70% ethanol. After ethanol treatment, cells were permeabilized using 
0.25% Triton X-100 at 4°C for 15 min and washed with PBS. Cells were stained with α-phospho 
Ser10-Histone H3 (pHH3) (Millipore) antibody in PBS/1% BSA (bovine serum albumin) for 2 
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hours at room temperature. After incubation, cells were washed once with PBS/1% BSA and 
stained with goat anti-rabbit Alexa fluor 647 secondary antibody (Invitrogen) for 30 minutes in 
the dark at room temperature. Cells were washed with PBS and resuspended in PBS. NucBlue™ 
DAPI stain (Invitrogen) was added to the samples prior to analysis using LSRII flow cytometer 
(BD Biosciences). All experiments were repeated in triplicate.  
 
Caspase-3 Activity Assays 
 Lung cancer cell lines were transfected with full-length FLAG-PAXIP1, pLK0.1 PAXIP1 
shRNA or tBRCT pair C2 of pNTAP-PAXIP1 along with their empty vector controls. Cells were 
treated with AZD1775 for the time points indicated and were collected and lysed using CHAPS 
lysis buffer [1% CHAPS, 150mM NaCl, 10mM Hepes pH 7.4, protease and phosphatase 
inhibitors]. Caspase-3 belongs to a family of proteases that is cleaved in reaction to the cell 
undergoing cell death. The caspase-3 enzymatic activity assays measure apoptosis indicated by   
the hydrolysis of the peptide substrate acetyl-Asp-Glu-Val-Asp-7-amido-4-methylcoumarin (Ac-
DEVD-AMC) by caspase-3, which results in the release of fluorescent 7-amino-4-
methylcoumarin (AMC). The excitation wavelength of Ac-DEVD-AMC is 360nm and the 
emission wavelength at which AMC is detected is 460nm. 25µg of protein lysates were used and 
the added to a 96-well plate in triplicate and the enzymatic activity was measured using a 
caspase-3 assay fluorimetric kit (Sigma). Results were reported as fluorescence units (FU)/µg 
Protein/hr and changes between different conditions were statistically analyzed by 2-tailed 
Student t test (GraphPad). Differences were considered significant at P values less than 0.05.  
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Flow Cytometry Based Caspase-3 Assays 
 Lung cancer cell lines were transfected with full-length FLAG-PAXIP1, pLK0.1 PAXIP1 
shRNA along with their empty vector controls. Cells were treated with AZD1775 and ionizing 
radiation (IR) for 6h, 12h and 24h as indicated. Cells were trypsinized, collected and washed 
twice with PBS. 106 cells were fixed in Cytofix/Cytoperm buffer (BD Biosciences). Cells were 
incubated for 20 minutes on ice. Cells were washed with BD Perm/Wash buffer and incubated 
with BV605 Caspase-3 antibody (BD Biosciences) for 30 minutes at room temperature. Cells 
were washed with BD Perm/Wash buffer and resuspended in the same buffer before being 
analyzed by a LSRII flow cytometer (BD Biosciences). Data was analyzed by FlowJo software.  
 
Drug Screening and Synergy Assessment 
 Viability assays were performed in 384-well microtiter plates with biological and 
technical duplicates. Viability was evaluated using the Cell Titer Glo assay (Promega) and 
luminescence was read on a SpectraMax M5 plate reader (Molecular Devices). The Cell Titer 
Glo assay measures cell viability by quantifying the ATP present in metabolically active cells.  
Cells were seeded at a density of 1000 cells/well. Drugs were added 24 h after plating and cells 
were incubated for another 72 h, 96 h (H1648) or 120 hours (H1395) based on their growth rate. 
For the synergy screens, control vehicle, cisplatin (4mM) and each secondary drug (at 0.5mM 
and 2.5mM) were used. For determining three-dimensional dose-response surfaces, drug 
concentrations in 4-fold dilutions ranged from 64mM to 0.25mM for cisplatin and 10mM to 
0.039mM for AZD1775. The maximum cisplatin concentrations in H1395 and H1648 cells were 
80mM and 128mM, respectively. Drug combination effects were evaluated by the Bliss model of 
independence [385] setting the cut-off for analysis to 1 standard deviation. 
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Immunohistochemistry and Tissue microarray (TMA) analysis  
For this study, we used two in-house TMAs with 106 and 150 lung cancer cases and 
controls, respectively. These were banked as part of the Lung SPORE initiative at the Moffitt 
Cancer Center. Patients provided informed consent and core biopsies and surgical resection 
specimens were embedded in paraffin blocks. Core sizes were 1 mm. Blocks were sectioned at 5 
µM and baked for 1 hour at 60°C. 
Of these, 95 and 138 lung tumors were analyzable (excluding those missing/unreadable) 
in the two TMAs. TMA1 consisted of mixed histologies with lung adenocarcinomas, squamous 
cell carcinomas, large cell neuroendocrine tumors and mesotheliomas. TMA2 lung tumors 
consisted exclusively of adenocarcinomas. Since these TMAs were underrepresented in 
squamous cell lung carcinomas, we utilized a commercial TMA3 (LC808; US Biomax Inc.) with 
80 squamous cell lung tumors. TMAs were stained using a Ventana Discovery XT automated 
system (Ventana Medical Systems, Tucson) as per manufacturer's protocol with proprietary 
reagents. All the slides were de-paraffinized on the automated system with EZ Prep solution 
(Ventana). For the α-WEE1 staining, heat-induced antigen retrieval method was used in Cell 
Conditioning 1 (Ventana). α-WEE1 mouse monoclonal antibody (sc-5285, Santa Cruz) was used 
at a 1:25 concentration in Dako antibody diluent (Carpenteria) and incubated for 60 min. The 
Ventana OmniMap anti-mouse secondary antibody was used for 16 min. For α-PAXIP1, heat-
induced antigen retrieval method was used in Ribo CC (Ventana). The rabbit primary antibody 
that reacts to PAXIP1 (HPA006694, Sigma) was used at a 1:20 concentration in Dako antibody 
diluent (Carpenteria) and incubated for 60 min. The Ventana OmniMap α-rabbit IgG secondary 
antibody was used for 8 minutes. For both stains, the detection system used was the Ventana 
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ChromoMap kit and slides were then counterstained with Hematoxylin. Slides were then 
dehydrated and coverslipped as per normal laboratory protocol. 
The stains were analyzed by a board-certified pathologist and scored based on the 
staining intensity. Cores were scored on a 0-4 scale with 0 being ‘no stain’ to 4 being the 
‘highest staining intensity’ corresponding to the positive control. Control tissue for WEE1 was 
normal placenta and for PAXIP1 was tonsil tissue. All cores with a score of 1-4 were considered 
‘positive’. 
 
Soft Agar Three-Dimensional Clonogenic Assays 
Tissue microarrays (TMAs) containing sections from 68 patient lung cancer explants that were 
subcutaneously passaged in nude mice (patient-derived tumor xenografts or PDXs) were 
obtained from Oncotest GmbH (Freiburg, Germany). The TMAs contained 33 lung 
adenocarcinomas, 19 lung epidermoid (squamous cell) carcinomas, 10 large cell and 6 small cell 
PDXs. This TMA was stained for PAXIP1 and WEE1 using immunohistochemistry as described. 
The staining was analyzed by a board-certified pathologist and scored. Two tumors with the 
highest PAXIP1 and WEE1 staining scores (PAXIP1+/WEE1+) and one tumor with high WEE1 
but no PAXIP1 (PAXIP1-/WEE1+) were selected to perform 3-dimensional clonogenic assays 
(tumor colony assay, TCA). Frozen cell suspensions were taken from the selected PDXs and 
were plated in soft agar in a 96-well plate format and a 5 X 5 matrix combination was applied for 
a combination of different concentrations of AZD1775 and cisplatin. Assay plates are prepared 
as follows: each test well contains 3 layers of equal volume, i.e. 2 layers of semi-solid medium 
(bottom and top layer) and one layer of medium supernatant, with or without the drugs being 
tested. The bottom layer consists of Iscove’s Modified Dulbecco’s Medium (Invitrogen), 
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supplemented with fetal calf serum (Sigma), gentamicin (Invitrogen) and agar (BD Biosciences). 
Tumor cells are added to the same culture medium supplemented with agar and plated onto the 
bottom layer. Four-fold dilution steps were used for each drug and different concentrations were 
selected for each tumor based on their response to cisplatin in vivo (previous data from 
Oncotest). Plates were incubated at 37°C for 8 to 13 days and colony growth was observed. All 
the colonies were imaged using an automated image analysis system and tumor growth/control 
growth (T/C) values were reported. This data was analyzed by the Bliss model of independence 
[385] and Chou-Talalay method [386] to determine synergy between AZD1775 and cisplatin 
when applied on the PDX models.   
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Chapter Five. PAXIP1 Potentiates WEE1 Inhibitor Action 
 
 
 
Introduction 
 
Cells have developed extensive networks and pathways that act to detect any DNA 
damage and repair DNA at the sites of damage [149]. Defects in DNA damage response (DDR) 
signaling can lead to genomic instability, a hallmark of cancer [92]. The DDR occurs with the 
help of a wide variety of protein complexes that sense DNA damage, promote DNA repair and 
coordinate with the cell cycle [153]. Modular interaction domains are discrete regions of a 
protein that can fold and function independently of the full-length context. Modular domains 
define the functional capacity of the protein by determining the molecular complexes with which 
it will participate. In the DDR network of proteins, many of the proteins contain the BRCA1 C-
terminus (BRCT) domain [8,16,17,23]. The BRCT domain can be found as a single domain, but 
can also exist in tandem pairs separated by short variable linker regions in proteins such as 
BRCA1, PAXIP1, MDC1 and TP53BP1 [11]. The tandem BRCT (tBRCT) domains are 
classically defined as phosphopeptide-binding domains that preferentially bind phosphorylated 
serine/threonine motifs, especially those generated by ATM/ATR [16,20,387]. Current 
chemotherapeutic regimens rely on perturbations in this DDR process and on the fact that cancer 
cells divide faster than normal cells and therefore, would be more sensitized to DNA damaging 
agents as compared to normal cells [388]. 
A previous study by Woods et al. performed a screen using tandem affinity purification 
coupled to mass spectrometry (TAP-MS), yeast two-hybrid (Y2H) and literature curation to 
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derive a protein-protein interaction network (PPIN) of proteins that are involved in the BRCT-
mediated DDR [22]. Seven tandem BRCT (tBRCT)-containing proteins were used, as baits to 
generate a comprehensive network comprised of 718 proteins and 1013 interactions, of which 
947 were novel. Because of the central role of kinase signaling in the DDR, the repertoire of 
kinases within the BRCT interaction network was also examined. A total of seventeen kinases 
were empirically identified in the network and predicted to play important roles in the regulation 
of the BRCT-mediated DDR (Figure 14). Therefore, we hypothesized that these kinases could be 
potential targets for therapy when used in combination with DNA damaging agents.  
Despite recent advances in targeted therapies, there have not been many improvements in 
long-term disease free survival in patients with lung cancer.  Single-agent platinum based 
therapies are employed in majority of the patients with lung cancer. However, these have shown 
to increase survival by few months, especially in advanced stage cancers [363,389]. Therefore, 
there is a need for new targets that can be used in conjunction with chemotherapy to increase the 
cure rate. Following our hypothesis that the kinases in the PPIN can act as chemosensitizers, we 
performed a systematic pharmacological screen with kinase inhibitors in combination with 
cisplatin in lung cancer cell lines. This dissertation analyzed serine/threonine kinases derived 
from the tBRCT PPIN and revealed WEE1 as the most effective target in these cell lines 
especially when WEE1 inhibition was combined with DNA damaging agents. The WEE1 protein 
is a key component of cell cycle regulation and an important target for therapeutic benefit in 
multiple cancer types. WEE1 is known to regulate the G2/M checkpoint by phosphorylating 
CDK1 [284,328,390,391] at the Tyr15 site along with Myt1 that phosphorylates CDK1 at its 
Thr15 site [313,392]. The phosphorylation of CDK1 by these two kinases keeps the cells in 
G2/M arrest post DNA damage until DNA repair has occurred [329,393,394]. When the cells are 
	  	   78 
ready to enter into mitosis, CDK1 is dephosphorylated by Cdc25A phosphatase [205,395]. 
WEE1 has shown to be overexpressed in multiple tumor types and is associated with  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. Seventeen protein kinases derived from a protein-protein interaction network.  
A previously generated protein-protein interaction network developed using seven BRCT-
containing proteins as baits (red nodes) were used to identify seventeen kinases (blue nodes) with 
a potential role in the DDR. 
 
poor survival in these cancers [335,396-398]. WEE1 activity has also been shown to cause 
resistance to DNA damaging agents and small molecule inhibitors such as AZD1775 (formerly, 
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MK-1775) have been used either as single agents or in combination with DNA damaging agents 
to overcome this resistance [212,334,336,345,347,355]. WEE1 inhibition is being used as a 
therapeutic strategy in many cancers; however, it is largely unknown as to what other DNA 
damage proteins may be involved in promoting effective response to WEE1 inhibitor therapy 
especially when used in combination with DNA damaging agents.  
In the study by Woods et al., WEE1 was found to interact with the C-terminal tBRCT of 
a protein called Pax transactivation domain-interacting protein (PTIP/PAXIP1) [22]. PAXIP1 is 
a BRCT-containing protein that has been shown to bind γH2AX [228] and TP53BP1 
[64,233,274] and in turn, shown to play a role in maintaining genomic stability [222,223]. It has 
also been shown that PAXIP1 is essential for cells to progress through mitosis [234]. As the role 
of PAXIP1 in the cell cycle has not been well studied, we hypothesized that its interaction with 
WEE1 may give insight into its role in mitotic progression. Therefore, in this dissertation, we 
studied the interaction between PAXIP1 and WEE1 and demonstrated that PAXIP1 regulates 
WEE1 kinase activity and PAXIP1 levels affect the response of the WEE1 inhibitor AZD1775. 
We show that PAXIP1 regulates WEE1 kinase activity and that PAXIP1 levels modulate the 
response of lung cancer cells to AZD1775. In patient samples, we observe that around a third of 
the lung tumors are PAXIP1 and WEE1 positive. Overall, we uncovered a novel role of PAXIP1 
in the cell cycle and propose the combination of PAXIP1 and WEE1 as candidate biomarkers for 
response to AZD1775 therapy. 
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Results 
 
 
Seventeen Kinases Bind BRCT-Containing Proteins in a DNA Damage Response 
Protein-Protein Interaction Network. A previous study from our lab employed a systems level 
approach to determine the protein-protein interaction network (PPIN) mediated by tandem 
BRCT (tBRCT) domains from seven proteins (BRCA1, MDC1, TP53BP1, PAXIP1, ECT2, 
LIG4, and BARD1) [22]. As previously described, these BRCT-containing proteins are known to 
be involved in the DDR. To determine potential sensitizers of DNA damaging therapies, we 
queried the network for protein kinases. Seventeen serine/threonine protein kinases were 
retrieved from this empirically determined tBRCT network interacting with six tBRCT proteins 
(Figure 15). Kinases that are highly expressed in tumors are known to be more effective targets 
due to oncogene addiction [399]. Therefore, to determine the prevalence of these kinases, their 
protein expression levels were quantified using liquid chromatography – multiple reaction 
monitoring mass spectrometry (LC-MRM) in 14 lung cancer cell lines and 1 non-cancer 
broncho-epithelial AALE line. Mutational status of the cell lines was determined using 
publically available databases (COSMIC, ATCC) (Table 4). Expression levels of the seventeen 
kinases varied amongst the different lung cancer cell lines (Figure 16). However, few of the cell 
lines H1395, H1648 had high expression of multiple kinases. Other cell lines H322, H1437 had 
lower expression of majority of the seventeen kinases. Therefore, these cell lines were further 
chosen for drug assessment studies to determine which of the DDR kinases are effective 
chemosensitizers. 
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Figure 15. DDR kinases and the BRCT-containing proteins they interact with in the PPIN. 
BRCT baits from the interaction network are represented on the left. Kinases found to interact 
with BRCT domains are represented as grey nodes on the right and are grouped by kinase 
classification. Node size is proportional to the degree of interactions for each node and the edges 
depict method(s) by which the interactions were identified (TAP: Tandem affinity purification, 
Y2H: Yeast-2-hybrid, LIT: Literature curation, STE: Serine/Threonine kinases, CMGC: CDK, 
MAPK, GSK3, CLK). 
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Table 4. Lung cell lines and their mutation status. 14 lung cancer cell lines and 1 broncho-
epithelial cell line with their p53, KRAS, EGFR, EML4-ALK alteration status (M-Mutant, WT- 
Wild-type) and whether they express WEE1 and PAXIP1 (‘+’ for expression, ‘-‘ for no 
expression as measured by Western blotting). 
 
 
 
 
 
 
 
 
 
 
WEE1 Was the Top Target in a Pharmacological Screen Targeting the Seventeen DDR 
Kinases 
 Next, we performed a pharmacological screen to target the DDR kinases in these lung 
cancer cell lines. All of the high expressing cell lines were negative for KRAS, the most common 
alteration found in lung cancer. Therefore, we also included few more cell lines with KRAS 
mutations to learn whether a KRAS mutation had an effect on the inhibitors. Eight lung cancer 
cell lines were subjected a systematic pharmacological drug combination screen targeting the 
seventeen kinases. 
Protein 
Kinase  
Peptide Sequence p53 PAXIP1 WEE1 KRAS EGFR EML4-
ALK 
H1666 Adenocarcinoma WT + + WT WT WT 
H522 Adenocarcinoma M + + WT WT WT 
ADLC-5M2 Adenocarcinoma WT + + WT WT WT 
H322 Adenocarcinoma M + + WT WT WT 
H1648 Adenocarcinoma M - + WT WT WT 
H2347 Adenocarcinoma M - + WT WT WT 
H1395 Adenocarcinoma WT + - WT WT WT 
H1437 Adenocarcinoma M - - WT WT WT 
H596 Adenocarcinoma M + + WT WT WT 
H1299 Adenocarcinoma M + + WT WT WT 
A549 Adenocarcinoma WT + + M WT WT 
H23 Adenocarcinoma M + + M WT WT 
PC9 Adenocarcinoma M + + WT M WT 
H3122 Adenocarcinoma M + - WT WT M 
AALE Tracheobronchia WT - + WT WT WT 
	  	   83 
 
 
Figure 16. Heatmap depicting the expression levels of the seventeen DDR kinases in 15 lung 
cell lines.                                                                                                                                   
Heatmap depicting the expression levels of the kinases in 15 lung cell lines measured by LC-
MRM (liquid chromatography-multiple reaction monitoring). 1 implies the cell line that ranks as 
the highest expressing cell line for that particular kinase and 15 is the lowest expressing cell line 
 
 A 36 compound panel was chosen to best cover the target kinases utilizing previously 
published information [400-403]. The kinases and their drugs targeting them are shown in the 
network (Figure 17). Some of the inhibitors had multiple kinase targets as can be seen in the 
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figure. Viability screens were performed using Cell Titer Glo assay on cell lines that were treated 
with the compounds alone and in combination with cisplatin. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17. 36 compound library to target the seventeen DDR kinases.                                    
A 36 compound library targeting the seventeen kinases was used to treat lung cancer cell lines in 
combination with cisplatin. The nodes indicate the different kinases each inhibitor targets. The 
numbers indicate the different inhibitors as shown in Figure 18.  
 
The viability ratio was calculated to evaluate the effect of combining a particular kinase 
inhibitor with cisplatin as opposed to using the kinase inhibitor alone (Figure 18). In the 
heatmap, higher viability ratio is indicated in yellow. This implies that adding cisplatin to the 
inhibitor led to increased cell death as compared to the inhibitor alone. The WEE1 inhibitor 
AZD1775 displayed the most pronounced and broadest increase in efficacy across several cell 
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lines when combined with cisplatin as compared to AZD1775 alone. Increased viability ratio was 
seen in multiple cell lines regardless of their KRAS mutation status. AT7519, a pan-CDK 
inhibitor demonstrated increased cell death alone, however, addition of cisplatin caused no 
significant increase in cell death. Therefore, this inhibitor is not an ideal chemosensitizer and 
therefore, as a result of the drug screen, we chose to focus our efforts on the WEE1 kinase.  
Analysis of the cisplatin/AZD1775 combination in H322 lung adenocarcinoma cells 
revealed pronounced synergy across a wide range of concentrations using the Bliss model of 
independence. The most pronounced synergy was observed at 0.625µM AZD1775 and 3µM 
cisplatin, which are concentrations available in physiological settings [404]. We therefore chose 
these concentrations for all further experiments with H322 cells unless otherwise stated.  
 
WEE1 Levels Do Not Directly Correlate With the Efficacy of AZD1775 
In previous studies, it has been indicated that WEE1 expression levels directly correlate 
with the sensitivity of cells to WEE1 inhibition [332]. Therefore, to assess the extent to which 
levels of WEE1 could predict response to AZD1775, we first determined the levels of WEE1 in 
fourteen lung cancer cell lines and the non-cancerous broncho-epithelial AALE cell line by 
western blotting (Figure 19). We quantified the WEE1 expression levels using densitometry 
analysis. Next, we determined the IC50 of AZD1775 in three cell lines with varying levels of 
WEE1 expression (Figure 20). Cell lines with high WEE1 expression, such as H322, were 
sensitive to AZD1775, whereas cells with low expression, such as H1395, did not respond to the 
inhibitor. 
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Figure 18. Heatmap showing the viability ratio of the 36 compound library targeting the 
DDR kinases.                                                                                                                                   
The heatmap depicts the viability ratio of the drug with cisplatin compared to the drug alone. 
Multiple lung cancer cell lines were treated with inhibitors shown here with and without 
cisplatin. The kinases targeted by each inhibitor are shown in Figure 17. 
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However, H1648 cells, which highly express WEE1, were markedly less sensitive to 
AZD1775 than H322 cells. To expand this analysis to a larger panel of cell lines and to evaluate 
whether WEE1 expression correlates with response to AZD1775, viability assays were 
performed by treating ten cell lines with AZD1775 for 72 hours. It was found that there was no 
direct correlation (r2 = 0.0013) between the WEE1 expression level and response to the inhibitor 
(Figure 21). Similar observations have been made in breast cancer; the effect of WEE1 inhibition 
was not dependent on the WEE1 expression levels. It was also shown that there was no WEE1 
amplification or mutations in the cell lines that were not sensitive to WEE1 inhibition but had 
high WEE1 expression [346]. Therefore, WEE1 inhibitor efficacy is not correlated with WEE1 
levels, making that an unlikely biomarker for AZD1775 therapy.  
The phosphorylation of the WEE1 substrate CDK1 at the Tyrosine 15 (pY15) site is another 
important measure used to evaluate the efficacy of the WEE1 inhibitor AZD1775 [334,345,355]. 
To evaluate whether the WEE1 expression levels correlate with the decrease in pY15-CDK1 
upon treatment, we measured the pY15-CDK1 levels in multiple cell lines upon 1 h of treatment 
with AZD1775 (Figure 22). As expected, H23 and H322 that express high levels of WEE1 
showed a marked decrease in pY15-CDK1 upon treatment. Conversely, H1395 and H1437, that 
do not have detectable WEE1 expression showed no decrease of pY15-CDK1 upon treatment. 
Intriguingly, H1648 cells express WEE1 but show mild decrease in pY15-CDK1 levels upon 
treatment (Figure 23). Taken together, these results indicate WEE1 protein levels alone may not 
a reliable measure of the effect of AZD1775 on the WEE1 kinase activity.  
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Figure 19. WEE1 expression levels in 15 lung cancer cell lines.                                           
WEE1 levels in fifteen lung cancer cell lines were quantified using densitometry analysis  
 
BRCT-Containing Protein PAXIP1 Interacts With WEE1  
As the WEE1 kinase was a part of the DDR protein-protein interaction network (PPIN), 
we focused on the tBRCT network to identify molecular determinants of WEE1 inhibitor 
sensitivity. In the tBRCT PPIN, WEE1 was identified in the mass spectrometry screen through 
the interaction with the PAXIP1 C-terminal tBRCT [22] and has also been shown to bind full-
length PAXIP1 in another mass spectrometry analysis (Unpublished data Woods et al.). PAXIP1 
is a BRCT-containing protein that plays a role in the DDR and is necessary for cells to progress 
to mitosis [234,274]. To confirm the interaction detected by mass spectrometry, the C-terminal 
tBRCT of PAXIP1 (tBRCT C2) and WEE1 were co-transfected into 293FT cells. 
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Figure 20. Dose-response curves of lung cancer cells in response to AZD1775.                   
Dose-response curves of three lung cancer cell lines with varying expression of WEE1. The cell 
lines expressing WEE1 had significantly lower IC50 values than those with no expression of 
WEE1 (H322: 0.45 µM, H1648: 1.23 µM, H1395: >10 µM). 
 
The interaction between tBRCT C2 of PAXIP1 and WEE1 was confirmed using pull down 
assays. Endogenous WEE1 was found to bind the ectopically expressed tBRCT C2 of PAXIP1 
(Figure 23). Immunoprecipitation with endogenous PAXIP1 antibody in H322 lung cancer cells 
indicated that endogenous WEE1 also binds full-length PAXIP1 under basal conditions (Figure 
23). No interaction was detected between WEE1 and BARD1, another BRCT-containing protein 
indicating that the interaction is specific to PAXIP1.   
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Figure 21. WEE1 expression does not correlate with AZD1775 activity.                            
WEE1 levels were quantified in the cell lines based on Figure 19. These lung cancer cell lines 
were treated with 2.5μM AZD1775 for 72 hours and percentage of viable cells were calculated 
using the CellTiterGlo assay. 
 
PAXIP1 Binds the Kinase Domain of WEE1 
PAXIP1 is a protein with three tBRCT domains. It has been shown that both the C-
terminal tBRCT domains – pair C1 and C2 bind phosphoproteins preferentially the p-S-X-X-F 
motifs [16] and WEE1 contains a SQEF motif in its kinase domain. To identify whether WEE1 
binds to any of the other tBRCT domains of PAXIP1, we fine-mapped the interaction of PAXIP1 
with WEE1 by performing pull down assays with all three tBRCT domains of PAXIP1 – N-
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terminal tBRCT (pair N1), the first C-terminal tBRCT (pair C1) and the second C-terminal 
tBRCT (pair C2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22. pY15-CDK1 levels change in cell lines that respond to the inhibitor.                 
pY15-CDK1 levels of cell lines upon 1 h of 0.5µM AZD1775 treatment. 
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Figure 23. BRCT-containing protein PAXIP1 binds WEE1.                                                   
Left Panel PAXIP1 tBRCT C2 was overexpressed in 293FT cells and pull downs were 
immunoblotted for endogenous WEE1. Right Panel Endogenous PAXIP1 and another BRCT-
containing protein BARD1 were immunoprecipitated in H322 lung adenocarcinoma cells and 
blotted for endogenous WEE1 
 
WEE1 was found to bind exclusively to the tBRCT C2 of PAXIP1 (Figure 24). As WEE1 
contains a SQEF motif in its kinase domain, we assessed whether the interaction between WEE1 
and PAXIP1 is phosphorylation dependent. PAXIP1 tBRCT C2 was transfected into 293FT cells 
and pull down assay was performed. The protein-streptavidin complexes were treated with either 
calf intestinal phosphatase (CIP) or with phosphatase treatment plus EDTA. Phosphatase 
treatment of the pull down complexes but not phosphatase treatment with consequent addition of 
phosphatase inhibitor EDTA reduced binding of WEE1 to PAXIP1 indicating that the interaction 
is modulated by phosphorylation (Figure 25).  
To further fine map the interaction, WEE1 was fragmented into three domains: N-
terminal (amino acids (aa) 1-291, fragment 1), kinase domain (aa 291-575, fragment 2) and C-
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terminal domain (aa 575-646, fragment 3). The fragments were cloned into the pDEST27 vector 
that is GST-tagged. The GST-tagged fragments were co-expressed (Figure 26) with the tBRCT 
C2 of PAXIP1 in 293FT cells. The tBRCT C2 of PAXIP1 was immunoprecipitated with 
streptavidin beads. It was found that only the kinase domain and the N- and C- terminal of 
WEE1 i.e. fragment 2 binds PAXIP1 and none of the WEE1 fragments bound the GFP control. 
This suggests that PAXIP1 may either be a substrate of WEE1 or may have a role in the 
regulation of WEE1.  
 
 
 
 
 
 
 
 
 
 
Figure 24. PAXIP1 tBRCT C2 and not tBRCT N1 or C1 binds endogenous WEE1.           
All the PAXIP1 tBRCTs, tBRCT N1, C1 and C2 were overexpressed in 293FT cells and pull 
downs using streptavidin beads. The beads were immunoblotted for endogenous WEE1. 
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Figure 25. The interaction between PAXIP1 and WEE1 is modulated by phosphorylation. 
tBRCT C2 of PAXIP1 was expressed in 293FT cells. It was pulled down using streptavidin 
beads and treated with phosphatase for 30 minutes. Change in WEE1 binding was tested. AKT 
was immunoprecipitated and p-S473 AKT levels were tested as an experimental control.  
 
PAXIP1 Disrupts the Phosphorylation of CDK1 by WEE1 
As PAXIP1 tBRCT C2 binds WEE1 at its kinase domain and the interaction is modulated by 
phosphorylation, we decided to determine the role of PAXIP1 in regulating the kinase activity of 
WEE1. To determine the functional impact of the PAXIP1-WEE1 interaction on the kinase 
activity of WEE1, we performed an in vitro kinase assay with recombinant WEE1, CDK1 and 
the tBRCT C2 of PAXIP1. WEE1 phosphorylated CDK1 at the Y15 site but introduction of the 
PAXIP1 tBRCT C2 fragment abrogated the phosphorylation of CDK1 by WEE1 (Figure 27). 
This suggests that PAXIP1 may regulate the WEE1-CDK1 interaction either through steric 
hindrance or through other mechanisms. To determine whether PAXIP1 is a phosphorylation 
target of WEE1 or CDK1, a CDK1 and WEE1 kinase assay was performed. 
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Figure 26. PAXIP1 binds the kinase domain of WEE1.  
WEE1 was fragmented into its N-terminal domain (fragment 1) and kinase domain (fragment 2) 
and the C-terminal domain (fragment 3) cloned into a GST-expressing vector. PAXIP1 tBRCT 
C2 binds WEE1 kinase domain and not its N- or C- terminal domain. 
 
As both CDK1 and WEE1 are tyrosine kinases, we observed that the PAXIP1 tBRCT C2 domain 
was not phosphorylated by either kinase in an in vitro kinase assay testing all tyrosine 
phosphorylations (Figure 28).  Using P-32 to detect all potential phosphorylations yielded the 
same result (Figure 29). This implies that PAXIP1 may not be a direct phosphorylation target of 
CDK1 or WEE1 but its binding to WEE1 plays a regulatory role in the phosphorylation of CDK1 
by WEE1 and potentially the G2/M checkpoint. 
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Figure 27. PAXIP1 disrupts the phosphorylation of CDK1 by WEE1.                                   
In vitro kinase assay with recombinant WEE1, CDK1 and PAXIP1 tBRCT C2 in GST-
expressing vectors. Kinase assay was performed at 30°C for 30 minutes. pY15-CDK1 levels 
were measured.  
 
To determine the effect of PAXIP1 on pY15-CDK1 levels in cells, PAXIP1 was knocked 
down in 293FT cells using shRNA. This led to increase in pY15-CDK1 levels as compared to 
control shRNA (Figure 30C). Knockdown of WEE1 also led to an increase in PAXIP1 levels 
(Figure 30A). However, knocking down PAXIP1 did not lead to change in WEE1 levels (Figure 
30B). This shows that PAXIP1 affects WEE1 kinase activity, however, decreased WEE1 levels 
do not affect PAXIP1. This suggests that there is a physical and functional crosstalk between 
PAXIP1 and WEE1, which may lead to cell cycle regulation. We test this in the sections that 
follow.  
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Figure 28. PAXIP1 is not a phosphorylation target of WEE1 or CDK1.                                 
In an in vitro kinase assay, recombinant PAXIP1 tBRCT C2, WEE1 and CDK1 were expressed. 
A Pan-phospho-tyrosine antibody was used to detect any phosphorylations.  
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Figure 29. PAXIP1 is not a phosphorylation target of WEE1 or CDK1.                                 
In an in vitro kinase assay, recombinant PAXIP1 tBRCT C2, WEE1 and CDK1 were expressed. 
γ-32P was used to detect any phosphorylations.  
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Figure 30. PAXIP1 levels are increased when WEE1 is knocked down.  
(A) Five shRNAs targeting WEE1 were expressed in 293FT cells. PAXIP1 levels were 
measured. (B) Four shRNAs targeting PAXIP1 were expressed in 293FT cells and WEE1 levels 
were measured. (C) PAXIP1 sh1 shRNA was expressed in 293FT cells and pY15-CDK1 levels 
were measured.  
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Overexpression of PAXIP1 Leads to an Increase in Mitotic Index at the G2/M Transition 
Upon Treatment With AZD1775 
As the previous experiments indicate, PAXIP1 may have a role in regulating the G2/M 
checkpoint by having an effect on its kinase activity. To assess the role of PAXIP1 at the G2/M 
checkpoint and how that affects the efficacy of the WEE1 inhibitor AZD1775, we performed cell 
cycle analysis using DAPI and phosho-Ser10 Histone H3 (pHH3) staining. Full-length PAXIP1 
was overexpressed in H322 cells and the cells were treated with AZD1775 followed by ionizing 
radiation (IR) and collected after 4 hours to assess early G2/M arrest. The percentage of cells 
currently undergoing mitosis (mitotic index) was measured using pHH3 staining. In cells with 
endogenous expression of PAXIP1, the mitotic index was increased in response to the 
combination of AZD1775 and IR as compared to control, AZD1775 only and IR only treatments. 
Treatment with AZD1775 alone led to a lower percentage of cells in G2 compared to the DMSO 
control (Figure 31A). The cells overexpressing PAXIP1 alone had no change in cell cycle or in 
mitotic index compared to control. However, cells overexpressing PAXIP1 treated with 
AZD1775 and IR had a higher mitotic index compared to any other condition (Figure 31B). This 
implies that upon DNA damage induction, with high levels of PAXIP1 more cells transition from 
G2 to M when WEE1 is inhibited. Conversely, cells with knocked down PAXIP1 when treated 
with AZD1775 and IR display a decrease in mitotic index compared to the DMSO treated cells 
(Figure 32). This indicates that PAXIP1 plays a role in transition of cells from G2 to M phase of 
the cell cycle.  
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Figure 31. Mitotic index increases in PAXIP1 overexpressing cells with AZD1775 
treatment  
Part A- Empty vector was transfected in H322 lung adenocarcinoma cells, cells were treated with 
0.5µM AZD1775 or DMSO control and with 6Gy IR. Cells were incubated for 4 hours and cell 
cycle analysis was performed to test the mitotic index (percentage of mitotic cells) at the early 
G2/M checkpoint post IR. 
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Figure 31. Mitotic index increases in PAXIP1 overexpressing cells with AZD1775 
treatment  
Part B - Full-length PAXIP1 was transfected in H322 lung adenocarcinoma cells, cells were 
treated with 0.5µM AZD1775 or DMSO control and with 6Gy IR. Cells were incubated for 4 
hours and cell cycle analysis was performed to test the mitotic index (percentage of mitotic cells) 
at the early G2/M checkpoint post IR. 
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Figure 32. Mitotic index decreases in PAXIP1 knockdown cells with AZD1775 treatment 
Part A - Scrambled control was transfected in H322 lung adenocarcinoma cells, cells were 
treated with 0.5µM AZD1775 or DMSO control and with 6Gy IR. Cells were incubated for 4 
hours and cell cycle analysis was performed to test the mitotic index at the early G2/M 
checkpoint post IR.  
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Figure 32. Mitotic index decreases in PAXIP1 knockdown cells with AZD1775 treatment 
Part B - shRNA targeting PAXIP1 were transfected in H322 lung adenocarcinoma cells, cells 
were treated with 0.5µM AZD1775 or DMSO control and with 6Gy IR. Cells were incubated for 
4 hours and cell cycle analysis was performed to test the mitotic index at the early G2/M 
checkpoint post IR. 
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Figure 33. Cell death increases in PAXIP1 overexpressing cells with AZD1775 treatment.  
(A) In H322 cells with overexpressed full length PAXIP1, caspase-3 activity was measured using 
a fluorometric assay after treatment with AZD1775 at the time points indicated. (B) In H322 
cells with PAXIP1 knockdown, caspase-3 activity was measured upon AZD1775 treatment. (C) 
PAXIP1 tBRCT C2 fragment was overexpressed in H322 cells and apoptosis was measured. 
(OE: overexpressed, IR: Ionizing radiation, p < 0.05 considered significant using paired t-test) 
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PAXIP1 Overexpression Leads To Increased Apoptosis Upon Treatment With AZD1775 
 Cells that have their DNA damaged during mitosis undergo apoptosis through mitotic 
catastrophe [405].  Cells treated with WEE1 inhibitors have been shown to undergo cell death by 
mitotic catastrophe when treated with DNA damaging agents [347]. To evaluate whether the 
increase in mitotic index observed when PAXIP1 is overexpressed and WEE1 is inhibited by 
AZD1775 translates to an increase in apoptotic cell death, we measured caspase-3 activity in 
H322 cells. Cells with overexpressed PAXIP1 and endogenous PAXIP1 were treated with 
AZD1775. The apoptosis levels, particularly in the first 24 h in cells overexpressing PAXIP1 
were higher compared to those with lower PAXIP1 levels (Figure 33A).  
H522 lung adenocarcinoma cells, which express high levels of WEE1, showed similar effects 
upon PAXIP1 overexpression (Figure 34). In contrast, H1395 cells, which do not express WEE1, 
did not exhibit increased apoptosis upon PAXIP1 overexpression (Figure 34). Conversely, knock 
down of PAXIP1 led to a significant decrease in cell death over 48 h consistent with the lack of 
effect on mitotic index (Figure 33B). This suggests that high levels of PAXIP1 are likely to 
correlate with a response to WEE1 inhibition alone or in combination with DNA damaging 
agents. As PAXIP1 binds to WEE1 at its tBRCT C2 site, we overexpressed that fragment of 
PAXIP1 in H322 cells and measured caspase-3 activity with AZD1775 treatment (Figure 33C).  
Over 24 h, an increase in apoptosis is observed similar to that obtained with full length PAXIP1. 
This indicates that the tBRCT C2 fragment of PAXIP1 mediates the increase in apoptosis we 
observe with PAXIP1 overexpression is combined with AZD1775.  
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Figure 34. Cells that do not express endogenous PAXIP1 do not exhibit increased cell death 
with overexpression.  
Empty vector or full-length PAXIP1 were transfected in H522 and H1395 lung adenocarcinoma 
cells. Cells were treated with 0.5µM AZD1775 or DMSO control and treated for 24 or 48 hours 
as indicated. Caspase-3 activity was measured using a fluorometric assay to measure apoptosis.  
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To observe the time course over which increase in apoptosis occurs and the percentage of 
AZD1775 treated cells that undergo apoptosis with and without PAXIP1, we analyzed H322 
cells that were treated with AZD1775 and IR over 6h, 12h and 24h time points. At 6 h, we 
observe a slight increase in apoptosis in cells that overexpress PAXIP1 and are treated with 
AZD1775 and IR as compared to those treated with AZD1775 and IR and transfected with an 
empty vector. We see a similar increase at 12 hours. However, at the 24 hours, we observe a 
greater increase in the percentage of caspase-3 positive in cells that have overexpressed PAXIP1 
as compared to cells that express endogenous PAXIP1 when treated with AZD1775 and IR. The 
percentage of caspase-3 positive cells with AZD1775 and IR is approximately 6% and the 
percentage of cells undergoing apoptosis with PAXIP1 overexpressed under the same conditions 
is about 14% (Figure 35). Similarly, when PAXIP1 was knocked down in H322 cells, half the 
number of cells are caspase-3 positive as compared to cells with endogenous PAXIP1 (Figure 
36). This suggests that the effect of PAXIP1 is observable once WEE1 has been inhibited over 
the long term. PAXIP1 may be considered a factor that further pushes cells towards mitotic 
catastrophe when WEE1 is inhibited and DNA is damaged. Taken together, it is observed that 
PAXIP1 may potentiate WEE1 inhibition effects by promoting mitotic catastrophe. 
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Figure 35. PAXIP1 overexpressed cells have double the caspase-3 positive cells as 
compared to cells with endogenous PAXIP1 when treated with AZD1775 and IR.  
Empty vector or full-length PAXIP1 were transfected into H322 lung adenocarcinoma cells. 
Cells were treated with 0.5µM AZD1775 or DMSO control and IR for 6, 12 or 24-hour time 
points as indicated. Percentages of caspase-3 positive cells were measured using flow cytometry.  
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Figure 36. PAXIP1 knock down cells have half the caspase-3 positive cells as compared to 
cells with endogenous PAXIP1 when treated with AZD1775 and IR.  
Empty vector or full-length PAXIP1 were transfected into H322 lung adenocarcinoma cells. 
Cells were treated with 0.5µM AZD1775 or DMSO control and IR for 6, 12 or 24 hour as 
indicated. Percentages of caspase-3 positive cells were measured using flow cytometry.  
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AZD1775 and Cisplatin Are Synergistic in Cells That Express Both WEE1 and PAXIP1 
As we observe in the caspase assays that cells that have the highest levels of apoptosis 
have a combination of high PAXIP1, WEE1 and were treated with AZD1775 and IR. Therefore, 
to test whether the response to AZD1775 in combination with cisplatin is dependent upon the 
PAXIP1 and/or WEE1 expression, H322, H157 and H1395 and H1648 were treated with 0.5µM  
AZD1775 and 4µM cisplatin for 1 h and WEE1, PAXIP1 and pY15-CDK1 levels were 
determined. Upon treatment H322 and H157 cells, which express both PAXIP1 and WEE1, 
showed reduced pY15-CDK1 levels (Figure 37). On the other hand, treatment does not affect 
pY15-CDK1 levels in H1648 and H1395, which express only WEE1 or PAXIP1, respectively 
(Figure 38). This may be due to a mutation or genetic change in WEE1 or PAXIP1 in these cell 
lines, however, it has been observed that in breast cancer WEE1 expression level varies but is not 
dependent on its mutation status [346]. Therefore, we suspect that this reduced WEE1 and 
PAXIP1 levels may be due to other reasons, such as epigenetic regulation.  
In addition, viability assays with AZD1775 in combination with cisplatin showed strong 
synergy in H322 and H157 cells (Figure 37). In contrast, cell lines such as H1648 and H1395 
that do not express both PAXIP1 and WEE1 displayed no significant synergy when analyzed 
using the Bliss Model of independence (Figure 38). Consistently, another cell line, H2170, that 
expresses PAXIP1 but not WEE1 showed no decrease in pY15-CDK1 and essentially no 
synergy. This suggests that the efficacy of AZD1775 and cisplatin combination is correlated to 
PAXIP1 and WEE1 levels in a cell.  
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Figure 37. Cells that express both PAXIP1 and WEE1 exhibit synergy with AZD1775 and 
cisplatin treatment                                                                                                                         
Left Panels Lung adenocarcinoma cell line H322 and a squamous lung cancer cell line H157 
were treated with AZD1775 and cisplatin either alone or in combination for 1 h and p-CDK1, 
PAXIP1 and WEE1 levels were measured. Right Panels Cell lines were treated with AZD1775 
and cisplatin for 72 h and synergy scores were calculated using the Bliss model of independence. 
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Figure 38. Cells that do not express WEE1 or PAXIP1 do not exhibit synergy with 
AZD1775 and cisplatin treatment Left Panels Lung adenocarcinoma cell lines H1648 and 
H1395 were treated with AZD1775 and cisplatin either alone or in combination for 1 h and p-
CDK1, PAXIP1 and WEE1 levels were measured. Right Panels Cell lines were treated with 
AZD1775 and cisplatin for 72 h and synergy scores were calculated using the Bliss model of 
independence. 
 
Prevalence of Lung Tumors With High WEE1 and PAXIP1 
Our cell line data indicated that for the combination of AZD1775 and cisplatin to be most 
effective, cells should express both PAXIP1 and WEE1. To assess the WEE1 and PAXIP1 levels 
in patient tumors, tissue microarrays that are part of the Lung Spore at the Moffitt Cancer Center 
were assessed using immunohistochemistry. 
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Three tissue microarrays (TMAs) with a total of 336 tumors were stained, of which 313 
tumors were analyzable by pathology or automated analysis. Figure 39 shows sample tumors that 
are positive or negative for WEE1 and/or PAXIP1. Both WEE1 and PAXIP1 are primarily 
nuclear stains, however, WEE1 also shows cytoplasmic staining (Figure 39). TMA1 contained 
95 tumors of multiple lung cancer histologies, TMA2 contained 138 adenocarcinoma tumors, 
and TMA3 contained 80 squamous cell tumors (Figure 40). 
Figure 39. Examples of WEE1 and PAXIP1 stained tumors                                                       
(A-D) Lung adenocarcinoma tumors with immunohistochemistry staining for WEE1, PAXIP1 
and H & E (Hematoxylin & Eosin). 
        
In Figure 40, the Circos plots depict the percentage of tumors that are positive for 
PAXIP1 and WEE1. The red ribbon shows the percentage of tumors that are positive for both 
proteins. Positive is considered any tumor with a 1+ or greater score of both proteins as assessed 
by a board-certified pathologist. 
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Figure 40. PAXIP1 and WEE1 positive tumors are prevalent in lung cancer.                    
Tissue microarrays were evaluated for tumors that are PAXIP1 and WEE1. In TMA1 with 
multiple lung histologies, 35% tumors were WEE1 and PAXIP1 positive. In an adenocarcinoma-
only TMA, TMA2, ~27% of the tumors are positive for WEE1 and PAXIP1 In a TMA with 
squamous cell carcinoma-only tumors, TMA3, 19% were positive for WEE1 and PAXIP1. 
 
We observed that 35% of the tumors co-expressed WEE1 and PAXIP1 in the first TMA (TMA1) 
across multiple histological subtypes (Figure 40 and Figure 41). In TMA2 and TMA3 (Figure 40 
and 42), it was observed that 27% and 19% tumors co-express WEE1 and PAXIP1, respectively. 
Thus, tumors expressing WEE1 and PAXIP1, which are expected to be the most sensitive to the 
combination of AZD1775 and cisplatin, are prevalent among lung tumors of multiple histologies. 
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Figure 41. Tissue microarray 1 composition                                                                                
(A) TMA1 WEE1 and PAXIP1 staining (B) 95 cases and 10 controls were analyzed in TMA1, 
percentage breakdown by histology (C) Percentage breakdown by histology and WEE1/PAXIP1 
staining status 
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Figure 42. Tissue microarray 2 and 3 composition                                                                      
(A) TMA2 WEE1 and PAXIP1 staining, breakdown by KRAS mutation and WEE1/PAXIP1 
staining status. (B) TMA3 – WEE1 and PAXIP1 staining. 
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Patient derived xenograft tumors containing both WEE1 and PAXIP1 exhibit synergy with 
AZD1775 and cisplatin 
Patient derived xenograft (PDX) lung cancer tumors were obtained on a tissue microarray and 
stained for PAXIP1 and WEE1. 68 lung tumors were stained and 3 tumors were selected, two 
with high PAXIP1 and WEE1 (PAXIP1+/WEE1+) expression and one with no PAXIP1 and high 
WEE1 (PAXIP1-/WEE1+) (Figure 43) to perform three-dimensional (3D) clonogenic assays. In 
the three tumors, AZD1775 was tested alone and in combination with cisplatin (matrix format 
with 5 x 5 concentrations) in 3 patient-derived xenografts of non-small cell lung cancer using a 
clonogenic assay (with image analyses as read-out). All the tumors were treated with 0 to 16µM 
of AZD1775 and 0 to 100µM of cisplatin depending on the tumor/control (T/C) growth value of 
the tumors in vivo. The xenografts were treated in 3-D clonogenic assays for 8 to 13 days and the 
synergy between AZD1775 and cisplatin was calculated using Chou-Talalay method. The 
method measures the tumor inhibition when the cells are treated with the drug combination and a 
combination index (CI) is derived. The T/C values were used to calculate the percentage of 
tumor inhibition. This data was then used to arrive on CI information. The –log10(CI) is called 
the pCI and the correlation of these values with synergy is mentioned in Figure 44. The first lung 
adenocarcinoma PDX tumor that expresses both WEE1 and PAXIP1 has a CI of 0.2 to 0.7 at 
physiologically relevant concentrations of AZD1775 and cisplatin (highlighted in red) indicating 
strong to moderate synergy of both the drugs (Figure 44). The second lung PDX tumor similarly 
expresses WEE1 and PAXIP1 and exhibits strong to moderate synergies at relevant 
concentrations of AZD1775 and cisplatin. This new technique has been used to simulate an in 
vivo setting and therefore, this indicates that tumors containing PAXIP1 and WEE1 in a 3-D 
clonogenic assay confirm what was observed in cell line data. Tumors that express both PAXIP1 
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and WEE1 are likely to have strong synergy with the drug combination of AZD1775 and 
cisplatin and therefore, should be ideal candidates for the combination therapy.  
Figure 43. WEE1 and PAXIP1 staining of patient-derived xenografts (PDXs) 
Two different tumors that were selected from a TMA of 68 lung tumors for the three-
dimensional clonogenic assays to test synergy of the combination of AZD1775 and cisplatin in 
these tumors. Tumors were stained for PAXIP1 and WEE1 using immunohistochemistry.     
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Figure 44. AZD1775 and cisplatin are synergistic in patient derived xenografts (PDX)  
PDXs were analyzed using Chou-talalay analysis. Left Panel Percentage of tumor inhibition with 
different concentrations of AZD1775 and cisplatin are indicated here. Right Panel Combination 
index (CI) values were obtained by applying the chou-talalay analysis to the percent inhibition 
values. CI values were –log(CI) transformed to pCI. pCI ranges are indicated in the table at the 
bottom of the figure.   
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Discussion and Future Work  
In this work, we exploited well-annotated interaction data obtained from a large scale 
protein-protein interaction network (PPIN) [22]. The interaction network focuses on seven 
BRCT-containing proteins that were found to be crucial for DNA damage response (DDR) and 
repair. We assessed inhibition of kinases in this DDR network for sensitization to cisplatin and 
identified WEE1 as a target in lung cancer cell lines. We further showed that response to the 
WEE1 inhibitor, AZD1775, alone or in combination with DNA damaging agents, such as 
cisplatin and ionizing radiation, is modulated by expression of the BRCT-containing protein 
PAXIP1 and WEE1. WEE1 and PAXIP1 interact and PAXIP1 potentially regulates WEE1 
kinase activity in vitro. Increased PAXIP1 levels lead to high levels of apoptosis when cells are 
treated with AZD1775 and ionizing radiation. Moreover, we demonstrate that lung tumors that 
express WEE1 and PAXIP1 are prevalent and are likely candidates to respond to the 
combination of AZD1775 and cisplatin. 
The function of WEE1 in the cell cycle has been studied extensively [291,406]. WEE1 is 
an atypical tyrosine kinase and its main phosphorylation target is CDK1 [284]. WEE1 and 
another mitotic kinase, Myt1, phosphorylate CDK1 at its Tyr15 and Thr14 sites, respectively 
[294]. These phosphorylations are important for CDK1 to remain inactivated until the cells are 
ready to enter mitosis. When cells are prepared for mitotic entry, CDC25 phosphatase 
dephosphorylates CDK1 and signals the entry of the cell into mitosis [290,322]. This process 
regulates the G2/M checkpoint. A significant number of tumors have a defective G1/S 
checkpoint due to p53 mutations, including 51.8% of lung adenocarcinomas and 79.3% of lung 
squamous carcinomas [407] and thus rely on the G2/M checkpoint for DNA repair. The reliance 
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of cancer cells on the G2/M checkpoint to prevent mitotic catastrophe provides a rationale for the 
use of pharmacological inhibition of G2/M checkpoint regulators.  
WEE1 inhibition by AZD1775 allows cells to transition to mitosis prematurely 
eventually leading to apoptosis [408]. Previous studies in multiple tumors such as lung cancer, 
sarcoma and glioblastoma showed that AZD1775 as a single agent or in combination with DNA 
damaging agents, such as IR or platinum compounds, leads to reduced tumor growth 
[334,336,355]. Our study builds on and extends this work by demonstrating a similar effect in 
multiple lung cancer cell lines with AZD1775, particularly in combination with cisplatin. 
Moreover, we show that WEE1 interacts with PAXIP1, whose activity modulates the cell 
response to AZD1775 as a single agent and when combined with DNA damaging agents.  
PAXIP1 contains three tandem BRCT (tBRCT) domains [233] and has been implicated 
in the DDR by binding to TP53BP1 using the C-terminal tBRCTs C1 and C2 [64,274]. PAXIP1 
has also been shown to regulate gene transcription and is important in preserving genomic 
stability [223]. PAXIP1 binds γH2AX [228], forms foci at sites of DNA damage [274] and is 
known to be involved in both non-homologous end joining and homologous recombination DNA 
repair processes [221,245]. PAXIP1 has recently also been shown to be important V(D)J 
recombination during the expansion of the immune repertoire [246]. The role of PAXIP1 in the 
cell cycle is less clear however, interestingly Ptip−/− mouse embryos cells do not progress to 
mitosis, arrest instead in G2 and undergo cell death [234].  
In our study, sustained high levels of PAXIP1 led to an increased mitotic index and 
apoptosis upon AZD1775 treatment alone or in combination with cisplatin. In lung cancer cell 
lines, we observed synergy of AZD1775 and cisplatin when the cells express both PAXIP1 and 
WEE1 (Figure 45). Interestingly, the effects of PAXIP1 depended on the presence of WEE1 
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(Figure 37 and 38). We further demonstrate that tBRCT C2 of PAXIP1 can directly inhibit the 
phosphorylation of CDK1 by WEE1 in vitro (Figure 27). However, it is unlikely that PAXIP1 
contribution to the robust response to AZD1775 can completely be attributed to this mechanism 
of direct inhibition. Taken together, our data suggest that while PAXIP1 may not be required for 
AZD1775 response, it plays a role in regulating, directly or indirectly, WEE1 activity at the 
G2/M checkpoint and may be necessary for a robust response. 
 The fact that 19% of squamous cell lung tumors and 27-35% of adenocarcinoma lung 
tumors in our series (Figure 40) express PAXIP1 and WEE1 provides the rationale for their 
exploration as potential biomarkers of AZD1775 combination therapy. Our cell line data 
indicates that the AZD1775 and cisplatin combination is effective irrespective of their status of 
EGFR, EML4-ALK, or KRAS alterations provided that cells express WEE1 and PAXIP1. This 
is important, as currently there is a lack of effective treatment modalities for lung tumors that are 
negative for oncogenic drivers such as EGFR, EML4-ALK etc.[409]. 
Based on the pre-clinical data from this study, a phase II clinical trial is being undertaken 
at the Moffitt Cancer Center and its partner sites, in collaboration with AstraZeneca. The primary 
goal of the clinical trial is to determine progression free survival in patients with squamous cell 
lung cancer when treated with carboplatin, paclitaxel with or without AZD1775.  Patients will 
also be assessed for pharmacodynamic endpoints in blood, skin and tumor tissue. WEE1, 
PAXIP1 and pY15-CDK1 levels will be assessed in all patient tumors using 
immunohistochemistry. This study will assist in determining whether patients with WEE1 and 
PAXIP1 exhibit a better response than patients that lack the expression of either of these proteins 
in their tumors. This translational study will help in establishing the efficacy of AZD1775 and 
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platinum combination therapy in squamous cell lung cancer and in assessing role of PAXIP1 as a 
candidate biomarker for the combination therapy.  
 
Figure 45. Schematic to represent the role of PAXIP1 in the regulation of the 
phosphorylation of CDK1 by WEE1.                                                                                     
PAXIP1 overexpression along with AZD1775 treatment (with cisplatin) in cells causes them to 
progress through mitosis and undergo apoptosis. Therefore, cells expressing both WEE1 and 
PAXIP1 have higher levels of apoptosis compared to those that do not express PAXIP1 and/or 
WEE1. 
 
In summary, our data on the PAXIP1-WEE1 axis derived from a systems approach. We 
provide new insight into determinants of the therapeutic effects of the WEE1 inhibitor AZD1775 
in lung cancer cell lines and propose that PAXIP1 and WEE1 levels in tumors could be used as 
potential biomarkers of response. This study also provides a platform to evaluate other DDR 
kinases and study their inhibitors and their interaction partners to develop novel therapeutics and 
biomarkers to be tested in a clinical setting. Furthermore, this study demonstrates the feasibility 
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and substantial potential of systems biology approaches to provide novel and clinically 
actionable hypotheses. 
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